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The p53 protein is considered as the guardian of the genome thanks to its important tumor 
suppressor roles such as cell-cycle arrest, apoptosis and senescence. Because these roles 
are extremely vital, the p53 pathway is strictly regulated. During unstressed conditions, 
p53 protein levels are kept in control by both ubiquitination of the p53 protein and 
inhibition of its transcriptional activity through the MDM2 and MDM4 proteins, 
respectively. Although MDM2 is the main modulator of p53 activity, there is a 
collaboration between MDM2 and MDM4 proteins to enable the control of p53. Thus, 
MDM4 is as important as MDM2 in this mechanism. In most human cancers, there is 
either a mutation in the Tp53 gene or an overexpression of its negative regulators. Thus, 
targeting the p53-MDM2-MDM4 interplay is one of the main aims of cancer therapeutics. 
Also, in some cancers, where there is overexpression of negative regulators, the use of 
inhibitors for only MDM2 is not enough to activate the p53 protein. For this reason, 
exploring inhibitors for MDM4 are vital for therapy. In this study, we aimed to optimize 
the purification of in silico designed nanobodies targeting the MDM4-p53 interaction and 
test their affinity and effectiveness by surface plasmon resonance (SPR) and a fluorescent 
two-hybrid (F2H) assay. 
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ÖZET 
 
 
 
p53 VE MDM4 ETKİLEŞİMİNİ BOZAN NANOBODİLERİN KEŞFİ 
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Anahtar Kelimeler: p53/MDM4 etkileşimi, nanobodiler, nanobodi saflaştırılması, 
floresan ikili hibrit tekniği, yüzey plasmon rezonans 
 
 
p53 proteini hücre bölünmesinin durdurulması, apoptoz ve senesens gibi önemli tümör 
baskılayıcı rolleri sayesinde genomun gardiyanı olarak bilinir. Bu roller son derece hayati 
olduğu için, p53 yolağı çok sıkı bir şekilde kontrol edilmelidir. Stres olmayan koşullarda, 
hücre içindeki p53 protein miktarı, p53 proteininin ubikutinlenmesi ve transkripsiyon 
aktivitesinin engellenmesi ile sırasıyla MDM2 ve MDM4 proteinleriyle kontrol altında 
tutulur. MDM2, p53 proteinin aktivitesinin ana modülatörü olmasına rağmen, p53’ ün 
kontrolünün sağlanması için MDM2 ve MDM4’ un işbirliğine ihtiyaç vardır. Bu nedenle, 
MDM4 proteini bu mekanizmada MDM2 proteini kadar önemlidir. Çoğu kanser tipinde, 
p53 proteininde mutasyon vardır ya da antagonistlerinin yüksek seviyede üretilmesi 
gözlenmiştir. Bu nedenle, kanser ilacı geliştirilmesinde p53-MDM2- MDM4 etkileşimi 
hedeflenmiştir. Buna ek olarak, antagonistlerin yüksek seviyede üretildiği bazı 
kanserlerde, sadece MDM2 için inhibitör kullanımı p53 proteinini aktive etmeye yeterli 
olmamıştır. Bu nedenle, MDM4 proteini için inhibitör araştırmaları önem kazanmıştır. 
Bu çalışmada bilgisayar ortamında tasarlanmış p53/ MDM4 etkileşimini bozan 
nanobodilerinin saflaştırılmasını optimize etmeyi ve bağlanmalarını yüzey plasmon 
rezonans (SPR) ve floresan ikili hibrit tekniği ile test etmeyi amaçladık. 
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1.   INTRODUCTION 
 
 
 
1.1.   Cancer Development 
 
 
Cancer cells divide in an uncontrolled manner compared to normal cells. Normal cells go 
through several control mechanisms that they regulate their growth- promoting signals 
which leads to cell division. However, in cancer cells these signals are not regulated and 
are hijacked produce their own growth factor ligands and through receptors they respond 
to these signals to divide without control (Hanahan and Weinberg 2011). This imbalance 
is due to genetic abnormalities like deletions, duplications, inversions and translocations 
which cause genetic instability (Thompson and Compton 2011) and  point mutations 
(Hart et al. 2015). If these genetic changes occur in genes like oncogenes, tumor- 
suppressor genes and stability genes, it is inevitable to observe tumorigenesis (Vogelstein 
and Kinzler 2004).  
 
Oncogene and tumor suppressor gene mutations work in a similar fashion. They increase 
by inducing cell division and preventing cell death or cell- cycle arrest (Hanahan and 
Weinberg 2000). On the other hand, stability genes control recombination during cell 
division and chromosomal segregation. These gene products prevent large scale genetic 
changes and when there is a mutation in these genes several other mutations occur with 
higher incidence. Cancer cells in general show evading apoptosis, self- production of 
growth signals, insensitivity to anti-growth signals, sustained angiogenesis, limitless 
replication and metastasis which are hallmarks of cancer development (Hanahan and 
Weinberg 2000). These mutations can occur in somatic cells which are in single cells and 
they do not show hereditary transmission. On the other hand, they can also occur in 
germline cells which will lead to hereditary predisposition to cancer development 
(Milholland et al. 2017). 
 2 
 
Proto- oncogenes are genes which when mutated, turn into oncogenes and affect cellular 
proliferation and cancer formation. Oncogenes are genes which can lead to cancer 
development and their mutation or change in expression causes gain-of-function effects 
(Osborne, Wilson, and Tripathy 2004). On the other hand, tumor suppressor genes 
negatively regulate the growth of cells or metastasis. When there is loss of function 
mutation, they can contribute to cancer development (Osborne, Wilson, and Tripathy 
2004). Discoveries or identification of these genes are very important because they can 
pave a way for the development of novel therapeutic applications which target these genes 
(Chen, Liu, and Qing 2018). ErbB2, PI3KCA and MYC are well studied example 
oncogenes and BRCA 1/2, PTEN and TP53 are also examples of tumor suppressors (Lee 
and Muller 2010).   
 
 
1.1.1.   p53 
 
The p53 protein is one of the most important tumor suppressors. It has very crucial role 
in inhibiting cancer development, this function can be understood from the observation 
of mutations in the TP53 gene in approximately 50% of human cancers (Brown et al. 
2009). The Wild type p53 gene induces G2/M and G1 cell-cycle arrest, senescence and 
apoptosis. p53 is a transcription factor and it was first discovered in 1979. This protein 
functions to sense cellular stresses like DNA damage, oncogene activation, viral infection 
and telomere shortening (Bourdon, Laurenzi, et al. 2003). Thus, p53 inhibits the increase 
in the number of damaged or stressed cells.  For all of these reasons, it is called guardian 
of the genome (Bourdon, Laurenzi, et al. 2003). Because p53 is a transcription factor, it 
binds to specific sequences on DNA in the regulatory regions of various genes and it does 
so as a tetramer. From various studies, in total 346 p53 target genes were found (Fischer 
2017). These genes have crucial functions in senescence, angiogenesis and autophagy 
(Joerger and Fersht 2016). During stress conditions, tetrameric p53 is activated by 
multiple phosphorylation events. According to the type of stress, activation of p53 leads 
to the upregulation or downregulation of target genes. In vertebrates p53 protein levels 
are regulated by the MDM2 and MDM4 proteins which are negative regulators. Under 
homeostasis condition, p53 gets ubiquitinated by MDM2 and MDM4 and gets degraded 
which keeps p53 protein levels very low (Joerger and Fersht 2016).  
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p53, as mentioned earlier, can lead to cell cycle arrest due to DNA damage and this is 
carried out with the activation of the transcription of the p21/ WAF1 gene, which encodes 
a small protein with 165 amino acids belonging to CIP/Kip family, a cyclin- dependent 
kinase inhibitor which results in  cell cycle arrest (Gartel 2006). It is the first p53 target 
gene which is found (El-deiry et al. 1993). After p53 is activated, it binds to the 5’ end of 
the p21 promoter and leads to the production of p21 mRNA. The p21 protein binds to 
CyclinE/ Cdk2 and Cyclin D/ Cdk4 and inhibits their activity (Georgakilas, Martin, and 
Bonner 2017). Retinoblastoma protein (pRb) phosphorylation, a substrate of these cdk’s 
is prevented in this way and pRb can bind to E2F1. With this binding, E2F1 is 
transcriptionally inactivated, so there is no transcription of E2F1 target genes related to 
DNA replication and cell-cycle which will lead to G1 arrest (Luo, Hurwitz, and Massagué 
1995). p53 activation also leads to G2/ M arrest through other p53 target genes like 14-3-
3σ and cdc25c (Martín-Caballero et al. 2001). After DNA repair and decrease in p53 
amounts, cells can through division again.  
 
Senescence, on the other hand, is due to the chronic activation of p53 which is triggered 
by telomere erosion, DNA damage signaling, disruption in chromatin organization and 
the activation of certain oncogenes (Beauséjour et al. 2003). Senescent cells have specific 
characteristics like, large cell size, active autophagy and increase secretion of 
proinflammatory cytokines (Campisi 2005). Cell cycle arrest via p53 is very crucial for 
senescence because without p21 there is no induction of senescence by p53. Although the 
common perception about senescence is that it is not reversible but cells can go through 
the cell cycle when there is inactivation of p53 (Beauséjour et al. 2003). The decision 
between cell cycle arrest and senescence is decided with the several pathways and their 
interaction with p53. Not only p53, but activities of pRb, NF-Kb and m-TOR are crucial 
for senescence. pRb causes formation of heterochromatin on E2F1 target genes and NF-
Kb is needed for proinflammatory cytokine expression (Chen 2016).  
 
Apart from cell cycle arrest and senescence induction, p53 activation can cause apoptosis 
in certain cell types. They can go through apoptosis instead of cell cycle arrest. After p53 
is activated transcriptionally with several stimuli, it induces several genes related to 
apoptosis signaling in addition to the genes mention above. These p53 targets are the BH3 
domain- only pro-apoptotic proteins such as Puma, Noxa, Bad, Bax and Bak, death 
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receptors like Fas and factors for apoptosis execution such as Apaf1 and caspase 6 (Chen 
2016). There are two apoptosis pathways; intrinsic and extrinsic (Figure 1.1). In the 
extrinsic apoptotic pathway, activation of death receptors like Fas causes dimerization of 
these receptors which is activates downstream signaling pathways such as the activation 
of procaspase 8 and the activation of caspase 3 and 7. On the other hand, the intrinsic 
pathway is the p53 dependent one in which p53 activation causes induction of BH3- only 
proteins. This induction causes mitochondrial membrane permeabilization (MOMP) 
which leads to cytochrome c, Smac and Omi release from the inter membrane space of 
mitochondria. The released cytochrome c binds to adenosine triphosphate (ATP) and 
Apoptotic Peptidase activating factor 1 (Apaf1) which forms apoptosome complex which 
in turn activates procaspase 9 and the executioner caspases 3 and 7 (Chen 2016). 
 
 
Figure 1.1 p53 downstream pathways When p53 is activated, depending on the severity 
of the damage, the cell can choose between apoptosis or cell cycle arrest. The p53 protein 
can activate genes related to both the intrinsic or extrinsic apoptosis pathways and also 
by activating p21, it can activate cell cycle arrest. 
 
 
1.1.2.   MDM2 and MDM4 
 
MDM2 
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In the late 1980s, the murine double minute 2 (MDM2) gene was identified. This is one 
of three unknown genes MDM1-3 which was observed in spontaneously transformed the 
3T3-DM mouse cell line (Cahilly-Snyder et al. 1987).  After several studies, it was found 
that MDM2 protein can bind and inhibit p53 (Momand et al. 1992) and also the oncogenic 
character of MDM2 was also revealed because the human gene homolog, HDM2 was 
found in human wild-type p53 sarcomas at high levels. In 10% of human cancers, the 
MDM2 gene was found to be amplified (Toledo and Wahl 2006). The oncogenic property 
of MDM2 is related with its ability to interact with and inhibit of p53. Because p53 is an 
important tumor suppressor, MDM2 itself should be controlled strictly; when needed 
such as under stress conditions, MDM2 should set p53 free so that it can reach and 
activate its target genes.  
 
The release of p53 is carried out by post-translational modifications of MDM2 which 
temporarily release p53 from inhibition. However, under conditions without stress, p53 
is kept under control so that it does not cause any unwanted cell cycle arrest, senescence 
or apoptosis (Shadfan, Lopez-Pajares, and Yuan 2013). This inhibition is done in two 
ways, by binding to the p53 transactivation domain which prevents the transcriptional 
activity of p53 (Figure 1.2) (Momand et al. 1992) or by acting as E3 ubiquitin ligase 
which leads to the delocalization of p53 from the nucleus and finally its proteosomal 
degradation (Shadfan, Lopez-Pajares, and Yuan 2013). The regulation of p53 is very 
important especially during embryonic development. The crucial function of the MDM2 
protein is shown with experiments including mdm2- null embryos which die in uteri. This 
lethality is rescued when the p53 gene is deleted. This finding demonstrates that the 
MDM2 protein carries out a paramount mission because without MDM2, cells go through 
apoptosis which is initiated as early as the blastocyst stage (3.5 days fertilization) in an 
uncontrolled manner due to uncontrolled activation of p53 (Chavez-Reyes et al. 2003). 
As a result, MDM2 deficient embryos are smaller than wild-type MDM2 containing ones 
and shows disorganized structure (Gannon and Jones 2012). 
 
MDM4 
 
Murine double minute 4 (MDM4) also in humans HDM4 or MDMX is a homolog of the 
MDM2 protein and was discovered from a cDNA library screen for attempting to identify 
binding partners of p53 (Shvarts et al. 1996). MDM4, similar to MDM2, is negative 
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regulator of p53. They share 34% protein homology. MDM4 is also overexpressed in 10-
20% of lung, stomach, breast and colon cancers and, 65% of retinoblastomas (Toledo and 
Wahl 2006). However, MDM4 has no E3 ubiquitin ligase activity like MDM2, it inhibits 
the activity of p53 by just binding to the p53 transactivation domain and also by forming 
a heterodimer with MDM2. This heterodimer is an effective degradation complex 
compared to a MDM2 homodimer (Gu et al. 2002). MDM4, on the other hand, cannot 
homo-oligomerize. MDM4 not only affects p53, but also MDM2 by increasing its 
stability during non-stress conditions. Binding of MDM4 prevents the auto-ubiquitination 
degradation of MDM2 (Gu et al. 2002). It can be said that MDM4 has a longer half- life 
compared to MDM2 because of this. For the effective regulation of p53, collaboration 
from both proteins is very important.  
 
Another difference between the two proteins is, the absence of nuclear localization and 
export signals in MDM4, which means that it needs MDM2 for  nuclear localization 
(Wade, Li, and Wahl 2013). While MDM2 is thought to be the main regulator of p53 
several mice experiments conducted in mice show that the loss of either MDM2 and 
MDM4 cannot be compensated. Thus, mdm4- null mice shows embryonic lethality at 
E8.5-9.5. Similar to mdm2- null mice models, this phenotype can be rescued by the 
deletion of p53 (Migliorini, Denchi, et al. 2002). Thus, MDM4 is another paramount 
negative regulator of p53 during development. Compared to mdm2- null mice, mdm4- 
null mice died later so there is a time difference. Another difference is, mdm4-null mice 
lethality is observed due to absence of cellular proliferation which is completely different 
in  the mdm2- null mouse model in which lethality is due to apoptosis (Gannon and Jones 
2012). In the mdm2- null mice embryo, lethality due to increased apoptosis can be rescued 
through the loss of BAX which is a pro-apoptotic and p53 target gene (Chavez-Reyes et 
al. 2003). On the other hand, in the mdm4- null mice embryo, lethality due to cell 
proliferation arrest is rescued by the loss of cyclin-dependent kinase inhibitor 1A 
(Cdkn1a) which encodes the p21 protein and a p53 target gene (Steinman et al. 2004). 
These differences show that, two similar negative regulators of p53 have non overlapping 
functions. 
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Figure 1.2 Summary of MDM2, MDM4 and p53 interaction MDM2 protein 
ubiquitinates both the MDM2s and MDM4 protein which inhibit the transcriptional 
activity of p53. Also p53 when it is activated can induce the expression of the MDM2 
protein which is important this negative feedback loop. 
 
 
1.2.   Structure of p53, MDM2 and MDM4 
 
 
p53 
 
Human p53 forms a homotetramer of 4x 393 amino acids in an active form. p53 is 
composed of an N-terminal transactivation domain (TAD) which is an intrinsically 
disordered and proline (Pro)- rich region (Figure 1.3). This is followed by a central a 
structured DNA-binding domain (DBD). This DBD domain is connected to a 
tetramerization domain with a linker. At the C terminus, an intrinsically disordered 
regulatory domain is present. This regulatory domain is mostly composed of basic amino 
acids and they bind DNA nonspecifically (Joerger and Fersht 2008). The N-terminal 
region contains two transactivation domains which are TAD1 (1-40) and TAD2 (40-61). 
These are intrinsically disordered and they are rich in acidic residues (Chang et al. 1995). 
The proline- rich region (amino acids 64-92) is crucial for binding to the transcription 
machinery (Thoden et al. 2008), the transcriptional coactivators p300/ CBP and the 
negative regulators MDM2 and MDM4 (Schon et al. 2002). Generally important 
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signaling proteins which are leading or cooperating in many pathways have disordered 
binding sites like in the case of the p53 TAD domain, this enables binding of several 
different target proteins (Itoh et al. 2018). After binding to its target, the TAD changes its 
conformation from a disordered to ordered state. TAD1 forms an α- helix when N-
terminal domain of both MDM2/MDM4 and the Taz2 domain of p300 binds. 
 
Tetramerization is important for p53, in in vitro tetramerization is not required for DNA 
binding but in vivo p53 without tetramerization ability, cannot efficiently acts as a 
transcription factor (Jeffrey, Gorina, and Pavletich 2016). Without any stress, p53 levels 
are low in cells and the main form of p53 in these cells are as monomers. During stress 
conditions, however, tetramerization of p53 is induced via post- translational 
modification like phosphorylation at serine-392 (Sakaguchi et al. 1997). Also when p53 
is activated, there is multiple phosphorylation at N terminal serine and threonine residues 
due to the activity of several protein kinases (Toledo and Wahl 2006). These post 
translational modifications cause a decline in the binding affinities of negative regulators 
like MDM2/MDM4, and strengthens the binding of the coactivators p300/ CBP (Lambert 
et al. 1998).  The proline- rich region links the TAD and DNA- binding domain in human 
p53. The function of the proline- rich region is not known clearly (Joerger and Fersht 
2008). On the other hand, the DNA binding domain contains an immunoglobulin-like β-
sandwich region. This enables binding to DNA. One half of the DNA binding domain 
docks to the DNA major groove and the other half is composed of large loops and 
stabilized by zinc ions (Joerger and Fersht 2008).  
 
MDM2 and MDM4 
 
MDM2 and MDM4 are structurally similar to each other (Figure 1.3). They have common 
domains like a N terminal p53 binding domain and a RING domain. Different from 
MDM4, MDM2 contains a nuclear localization signals and acidic domain. MDM2 and 
MDM4 interacts with p53 using a binding domain which is located at the N terminus (J 
Chen, Marechal, and Levine 1993). MDM2 and MDM4 have very similar p53 binding 
domains in which the amino acids needed for interaction between p53 are conserved 
(Freedman et al. 1997). With the binding of these proteins to p53, its transcriptional 
activity is prevented. p53 binding to this domain of MDM2 is targeted through several 
drugs like Nutlins (Carvajal et al. 2004). Although there is around 80% similarity between 
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the MDM2 and MDM4 p53 binding domains, Nutlin-3a does not bind to the MDM4 p53 
binding domain due to the different  topologies and electrostatic potentials of these 
domains of the two proteins (Karim 2017). This difference can also be understood from 
binding affinity of MDM2 and MDM4 towards p53. The MDM2 p53 binding domain has 
a higher affinity for p53 compared to that of MDM4 which can be explained by the ability 
of MDM2 with this enhanced affinity to shuttle p53 protein out of the nucleus for 
degradation (Joseph et al. 2010). 
 
Another common domain between MDM2 and MDM4 is the RING (Really Interesting 
New Gene) domain. Through their RING domains, MDM2 and MDM4 can form 
heterodimers. In addition to this ability to form heterodimers, the MDM2 RING domain 
has a special function. With the help of this domain MDM2 has E3 ubiquitin ligase 
activity (Honda, Tanaka, and Yasuda 1997).  E3 ubiquitin ligases generally have RING 
domains which enables interactions between proteins. By this activity MDM2 can target 
p53, MDM4 and itself for proteasomal degradation which is important for the negative 
feedback loop of MDM2-MDM4 and p53. Hetero dimerized MDM2 and MDM4 proteins 
were shown to be more efficient negative regulators of p53 than homodimers. This result 
is related with the ubiquitination catalyzed by MDM2.  MDM2 homodimer by itself can 
only carry out the multiple monoubiquitination of p53 (Lai et al. 2001) but several studies 
shows that the MDM2/ MDM4 heterodimer is more effective provider of 
polyubiquitination (X. Wang, Wang, and Jiang 2011). For degradation mainly 
polyubiquitination is needed because this is a recognition signal for the 26S proteosome. 
On the hand, monoubiquitination has different roles independent from degradation such 
as endocytosis and transcriptional regulation (Hicke and Dunn 2003). 
 
The acidic domain and nuclear localization/ export sequences are only present in MDM2. 
The function of the acidic domain is controversial. There are some studies showing that 
the acidic domain is also needed for the E3 ligase activity of MDM2 (Kawai, 
Wiederschain, and Yuan 2003). On the other hand, nuclear localization sequences are 
very crucial for MDM2 to carry out its vital role. When there is no stress, MDM2 is 
localized in the nucleus but with the help of both its nuclear localization and nuclear 
export sequences, it can shuttle between the cytoplasm and nucleus (Roth et al. 1998). 
Because MDM4 lacks a nuclear localization and export signal, it is generally located in 
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the cytoplasm when there is no MDM2 to shuttle it into the nucleus (Migliorini, Danovi, 
et al. 2002).  
 
 
Figure 1.3 Gene structures of MDM2, MDM4 and p53 Full length MDM2 and MDM4 
each have a p53 binding domain, an acidic domain, a zinc finger domain and a RING 
finger domain in common. MDM2, different from MDM4, has a nuclear localization 
signal (NLS) and nuclear export signal (NES). p53 has a transactivation domain, proline 
rich domain, DNA binding domain, tetramerization domain and C-terminal regulatory 
domain. 
 
 
1.3.   Regulation of MDM2, MDM4 and p53 During Stress Conditions 
 
 
When there is no stress, p53 is kept under control through both MDM2 and MDM4 
(Figure 1.4). With the ubiquitination activity of MDM2, p53 is shuttled from the nucleus 
to the cytoplasm and undergoes P26 proteasome dependent degradation which keeps p53 
levels a low steady state level. However, during stress conditions, p53 is released to carry 
out its function as the guardian of the cell. This equilibrium is enabled with several 
different proteins which are induced in different stress conditions. When there is no stress 
in the cell, an important ubiquitin- specific protease, HAUSP (Herpes virus- associated 
ubiquitin- specific protease) increases the stability of MDM2, MDM4 and p53 by 
decreasing the self ubiquitinating activity of MDM2 (Sheng et al. 2006). Also, Death- 
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domain associated protein (Daxx) is cooperates with both MDM2 and HAUSP and this 
complex increases the stability of MDM2 in the cell (Toledo and Wahl 2007).  
 
After DNA damage occurs in the cell, a cascade of kinase reactions is initiated and several 
different proteins are recruited to the damage site (Figure 1.4). These activated kinases 
phosphorylate p53 to induce cell cycle arrest, apoptosis or senescence (Shadfan, Lopez-
Pajares, and Yuan 2013). The main kinase in this cascade is, ATM (Ataxia Telangiectasia 
Mutated) which is activating p53. The general regulation of p53 level is controlled by the 
post-translational modifications on negative regulators or on the p53 protein itself.  When 
ATM kinase is activated, it phosphorylates MDM2 at S395 which is located in the RING 
domain (Maya et al. 2001). In addition to this phosphorylation, ATM also phosphorylates 
p53 at S15 which allows p53 to escape MDM2 inhibition. This increases the 
transcriptional activity of p53 (Shieh et al. 1997),(Lambert et al. 1998). MDM2 stops p53 
degradation and cytoplasmic export. A second DNA damage induced kinase is DNA-PK 
(DNA- activated Protein Kinase) which phosphorylates MDM2 again but in a different 
domain, on S17 in the p53- binding domain (Mayo, Turchi, and Berberich 1997). This 
modification in the p53 binding domain decreases the binding strength between p53 and 
MDM2. p53 released from MDM2 inhibition can activate downstream signaling 
pathways. On the other hand, ATM phosphorylates MDM4 at S403, this modification 
causes MDM4 to be targeted by MDM2 for proteasomal degradation (Pereg et al. 2005).  
Overall, these post translational modifications remove p53 from MDM2 and result in 
MDM2 changing its ubiquitination target from p53 to MDM4. Because MDM4 is 
degraded, MDM2 is not stable anymore and it degrades itself too. On the other hand, 
activated p53 transcriptional activity causes an increase in MDM2 levels which prevents 
an uncontrolled increase in p53 activity.  
 
The mitogenic signals causes activation of several proteins. E2F1 controls the 
transcription of many genes related to G1 and S phase in the cell cycle. Also it causes 
accumulation of ARF (Alternate open Reading Fame of locus p16INK4a) which will 
eventually leads to p53 activation (Zhu et al. 1999) by preventing the ubiquitination of 
MDM2 bound to p53. ARF does this by sequestering MDM2 in the nucleolus which will 
causes the separation of p53 from MDM2 which ubiquitinates MDM4 and itself as 
mentioned above. Also it was shown that ARF can interact with MDM4 and like in the 
case of MDM2, it can sequester MDM4 within the nucleolus (Jackson, Lindström, and 
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Berberich 2001). Also K-Ras and insulin-like growth factor-1 (IGF-1) can have an effect 
on MDM4 levels (Gilkes et al. 2008). p53 is activated when there is a problem with the 
regulation of ribosomal biogenesis. This activation is done by ribosomal proteins like L5, 
L12, L23 and S7. Also the binding of these ribosomal proteins to MDM2 initiate the 
degradation of MDM4, further releasing p53 from inhibition (Gilkes, Chen, and Chen 
2006). 
 
  
Figure 1.4 MDM2, MDM4 and p53 pathway When there is no stress, MDM4 and 
MDM2 heterodimerize using their RING domains, inhibits transcriptional activity of p53 
protein and ubiquitinates the p53 protein and target it for proteosomal degradation. When 
there is stress or DNA damage, p53 tetramers gets phosphorylated by several kinases and 
this causes the translocation of p53 into the nucleus. Inside the nucleus p53 activated the 
transcription of genes related to cell cycle arrest or apoptosis, according to the levels of 
damage. 
 
 
1.4.   Targeting the MDM4- p53 Interaction for Cancer Treatment 
 
 
MDM2 is overexpressed in several cancer types like sarcomas, gliomas, melanomas and 
carcinomas (Onel and Cordon-Cardo 2004). In these cancer types, generally p53 is in 
wild type form. That’s why MDM2 antagonist research is very crucial. Structural analysis 
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of MDM2 and p53 binding interface is essential. In this interface, three amino acids, F19, 
W23, L26 on p53 interact with MDM2, the small area of interaction is suitable for 
inhibition by small peptides or molecules (Chène 2004). One of the first compounds 
targeting the MDM2-p53 interaction is Nutlin-3a. This compound is a cis- imidazolidine 
derivative and it binds MDM2 with IC50= 90 nM (Vassilev 2004). In in vitro experiments, 
it as shown that Nutlin-3a separates p53 from MDM2. Tumor shrinkage and no induction 
in toxicity is observed in experiments with nude mice containing human xenografts 
tumors treated with Nutlin-3a (Toledo and Wahl 2007).  
 
The second type of inhibitors are spiro- oxindoles (Shangary and Wang 2009) and third 
group is  the benzodiapinedione family (Grasberger et al. 2005). AM-7209 is another 
known and effective MDM2 inhibitor with KD (dissociation constant) 38 pM. N- terminal 
part of MDM2 (6-24) when binds to AM-7209 becomes ordered and it folds on to the 
ligand which will end up in interfering with p53 binding (Rew et al. 2014). Although 
these compounds show high affinity towards MDM2, they have low affinity towards 
MDM4. Some studies show that MDM4 inhibition is more suitable and less hazardous 
compared to MDM2 inhibition. When MDM2 inhibitors are given, it is very possible that 
normal adult tissues can enter apoptosis, induced by p53 (Marine and Lozano 2009). 
However, MDM4 inhibitors shows no hazardous effect on normal adult tissues (Garcia 
et al. 2011). In addition to this, it is found that Nutlin-3a is ineffective in cells where there 
is MDM4 overexpression (Hu et al. 2006). These results shows that, MDM4 is also a 
crucial target for cancer therapy. MDM4 is overexpressed in solid tumors like cutaneous 
melanoma, retinoblastoma and hematological malignances and it is also overexpressed in 
65% of human melanomas (Gembarska et al. 2012). For these cancer types, MDM4 is a 
target for therapeutics. Although, clinical trials for small molecule inhibitors of MDM4 
is limited, there is still a research going on to find more potent inhibitors for MDM4. 
 
There are several small molecules targeting MDM4 such as WK298, the binding of 
WK298 is similar to binding of p53 peptide, it has EC50= 20µM (Popowicz et al. 2010). 
On the other hand, SJ-172550 is the first small molecule inhibitor of MDM4 binding to 
the N- terminal p53 interaction pocket (Reed et al. 2010). It binds to MDM4 with a EC50= 
5µM and it successfully disrupts its interaction with p53 (Reed et al. 2010).  There is 
another study which shows a high throughput screening result for MDM4 inhibitors; three 
candidates are NSC207895, NSC146109 and NSC25485 (Wang et al. 2012). NSC207895 
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has less toxicity and shows dose dependent increase in binding to MDM4 and also they 
showed that it enhances p53 transcriptional activity and inhibits p53 degradation.  
 
Another class of inhibitors are single domain antibodies. These single domain antibodies 
bind the p53 binding domain of MDM4. In order to find the best binding single domain 
antibody, a selection was performed using a synthetic single- domain VH library with 
random complementarity- determining regions. After multiple rounds of selection, 
binders were screened by ELISA and their efficiency of separation of a p53 peptide from 
the MDM4 N terminal cleft was evaluated. After selection, a single domain antibody 
(VH9) was found to be the best binder with an affinity of 44 nM against MDM4 (Yu et 
al. 2009). This study demonstrated that, single domain antibodies can also be used for 
targeting the interaction between MDM4 and p53. 
 
 
1.5.   Nanobodies 
  
 
1.5.1.   Discovery, Structure and Advantages 
 
Other than small molecule or peptide inhibitors as drugs, antibody- based drugs are highly 
advantageous as therapeutics for several diseases like cancer, inflammatory diseases, 
infectious disease and allergies (Mullard 2015). Monoclonal antibodies (MAbs) are the 
mostly used antibody type for several purposes. They are antibodies produced by a single 
B lymphocyte clone. Although they have some advantages, they are not easy to produce 
and their cost of production is very high. Also they have a large size which is 150 kDa 
(Figure 1.5) (10- 15 nm long and 7-9 nm wide) and this is a limitation for tissue 
penetration especially very important in case of tumor therapy. In addition to this, they 
can initiate unwanted immune responses and because of the half- life which is several 
days, they are not useful for molecular imaging (Lipman et al. 2005). A new type of 
antibody was discovered in the 1990s by the Hamers- Casterman group, called heavy 
chain only antibodies (HcAbs) which are found in members of the Camelidae family 
(camels, llamas, alpacas and dromedaries) and sharks. These animals contain both 
conventional immunoglobulin G antibodies (IgG) and these heavy chain only antibodies 
in their sera. Heavy chain only antibodies do not have light chain and first constant 
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domain. In overall, they contain two constant domains CH2 and CH3, a hinge and antigen 
binding domain in other words variable heavy chain domain (VHH) (Hamers-Casterman 
et al. 1993). The VHH domain was recently expressed as a single domain and 
trademarked as Nanobody® by the Ablynx company.  
 
 
Figure 1.5 Representation of conventional antibodies, heavy chain only antibodies 
and nanobodies. The antigen binding domain is labelled in purple. For conventional 
antibodies, this domain is made up of both the heavy and light chains. Nanobodies are 
biotechnologically developed antibodies composed of only the antigen binding domain. 
 
The VHH part of the HcAbs contains just the antigen binding portion and it still has 
antigen binding capability. The size of the nanobodies are around 15 kDa (4nm long and 
2.5 nm wide) (Van Audenhove and Gettemans 2016). VHHs contain four framework 
regions and between them there are three complementarity- determining regions (CDR)  
(Muyldermans et al. 2009). The VHH domain has an Ig fold of two beta-sheets, those 
beta strands are connected via loops which are responsible for antigen recognition. The 
loops are connected via disulfide bonds generally so that they are not flexible and this 
provides antigen binding (Beghein and Gettemans 2017). In conventional antibodies, the 
framework region 2 (FR2) of VHs has lots of hydrophobic amino acids which enable their 
interaction with VLs but in nanobodies this region is exposed and does not participate in 
molecular interactions so it is replaced with hydrophilic amino acids (V37F, G44E, L45R 
and W47G). This change explains the high solubility of nanobodies and their decreased 
propensity for aggregation (Muyldermans 2013). The CDR3 loop is the main antigen 
binding domain of nanobodies and it provides 60- 80% of the contacts with the antigen 
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compared to CDR1 and CDR2 (De Genst et al. 2006). Also the CDR3 loop has a convex 
structure which provides binding to cavities or hidden epitopes on antigen surface like 
active site of enzymes and they mostly bind to conformational epitopes (De Genst et al. 
2006). In addition to this, CDR1 and CDR3 loops in nanobodies are longer compared to 
conventional antibodies.  
 
Nanobodies have advantages in size, stability and solubility. Also they have special 
physical and chemical robustness. During the nanobody selection process to select the 
best binding nanobody, harsh selection procedures can be applied like extreme 
temperatures, selection with presence of proteases, high pressure and low pH (Renisio et 
al. 2001). Nanobodies have good shelf- life, they are very stable and do not lose their 
binding activities when they are incubated in 37oC for 1 week (Ghahroudi et al. 1997). 
They can resist high temperatures like 90 oC (Linden et al. 1999). Their stability is not 
destroyed with the use of chaotropic agents (Dumoulin et al. 2002). In addition to this, 
nanobodies do not cause unwanted immune response when administrated in the human 
body. This is likely due to their lack of Fc regions, a property that prevents them from 
undergoing Fc receptor dependent internalization. In contrast to normal IgG molecules 
undergo rapid clearance from the blood (Muyldermans 2013).  
 
Another advantage of nanobodies is their ability to generate multidomain constructs 
(Saerens, Ghassabeh, and Muyldermans 2008). Nanobodies due their size and stability 
shows a monomeric behavior, this enables ease in generation of multidomain nanobodies 
like bivalent monospecific nanobodies with high avidity towards antigen or biparatopic, 
monospecific nanobodies binding to different epitopes on the same antigen which again 
increases the avidity (Emmerson et al. 2011). Also bivalent nanobodies which are binding 
to two different antigens can be generated (Conrath et al. 2001). Nanobodies are encoded 
by a single gene which is approximately 360 base pairs can be easily linked to different 
molecules like fluorescent proteins, this structure is called a Chromobody®. They are 
very useful for real-time visualization of intracellular proteins (Rothbauer et al. 2006). 
Moreover, for in vivo imaging purposes, they can be linked to radionucleotides or near-
infrared fluorophores (Chakravarty, Goel, and Cai 2014). In addition to these advantages, 
nanobodies can be expressed in very high amounts economically in microorganisms like 
bacteria (Escherichia coli) and yeast (Saccharomyces cerevisiae), also in mammalian cell 
lines and plants (Frenken et al. 2000),(Ismaili et al. 2007). 
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1.5.2.   Production methods for nanobodies 
 
In order to generate nanobodies for a specific antigen, several selection steps should be 
carried out to find the best binding nanobody. Generally, the method for this selection 
contains, generation of a nanobody library, panning from that library and after selection, 
production of that nanobody in E. coli or S. cerevisiae followed by His-Tag or GST-tag 
affinity purification. Initially, to form a nanobody library llamas were subcutaneously 
injected with the desired antigen together with Freund’s complete adjuvant. Before and 
after each immunization the sera of the immunized llama were collected and the antibody 
titers were checked with ELISA. After the last immunization, blood samples from the 
llama were taken and peripheral blood mononuclear lymphocytes (PBMCs) were 
isolated. Total RNA was isolated and a cDNA library was produced with reverse 
transcription (Kazemi-lomedasht, Behdani, and Pooshang 2015). Because all nanobodies 
are encoded by a single exon and each exon has similar sequences at the beginning and 
at the end, the same single set of primers can be used to amplify the nanobody genes 
(Revets, De Baetselier, and Muyldermans 2005).  
 
In the second step, nested PCR is used to amplify more and to add specific restriction 
sites for cloning. After digestion with the desired restriction enzymes the nanobody 
sequences were ligated into a plasmid/phagemid, generating a library of nanobody genes 
(Ghahroudi et al. 1997). The VHH library in this phagemid were transferred to 
bacteriophages for in vitro phage display.  Each phage (approximately 1012) displays a 
unique nanobody on its surface from the library (which can have a complexity of 106- 
1011) (Bazan, Całkosiński, and Gamian 2012). The screening procedure is a multi-step 
procedure, each step selecting nanobodies with highest binding affinity. The selected 
nanobody displaying bacteriophage particles are further selected with increasing the 
washing solution’s stringency in each step for several rounds. Phages displaying strong 
antigen binding nanobodies are not eliminated but others are eliminated due to this harsh 
selection procedure. After the last step of panning, bacteriophages are used to infect 
bacteria and individual colonies are used to purify nanobody proteins and identify their 
binding affinities (Ebrahimizadeh and Rajabibazl 2014).  
Because nanobodies contain disulfide bonds and the bacterial cytoplasm is a reducing 
environment, is not a suitable for the formation of disulfide bonds (Stewart, Åslund, and 
Beckwith 1998). On the other hand, the bacterial periplasm, with disulfide bond (Dsb) 
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catalysts, peptidyl-proyl cis/ trans isomerases and chaperones (Salema and Fernández 
2013), is a favorable environment for the folding of nanobodies. With the help of vectors 
containing an N- terminal pelB leader and C- terminal protein tag like the hexa- histidine 
tag, selected nanobodies can be expressed and purified using periplasmic purification 
methods and further purified by immobilized metal- affinity chromatography (IMAC) 
(Salema and Fernández 2013). Following this purification, the binding affinities of 
individual nanobodies can be determined by surface plasmon resonance or ELISA 
techniques. Recently the in vivo steps of nanobody library generation were bypassed by 
the generation of naïve libraries that were selected by phage display. In this way, animal 
immunization  were eliminated and high affinity nanobodies were selected by panning 
nanobodies (Revets, De Baetselier, and Muyldermans 2005). In addition to phage display, 
ribosomal or yeast display methods can also be used for the selection of nanobodies. 
 
In addition to nanobody selection from library using display methods, there are also some 
studies showing that nanobody binding can be optimized by in silico modelling. Models 
contain in silico site-directed mutagenesis and molecular dynamics simulations to 
visualize and measure the binding affinities of mutated nanobodies (Farasat et al. 2016). 
This study generated higher affinity variants of a wild type EGFR binding nanobody 
which is used for treatment or diagnosis of cancer. This nanobody is selected from a 
library by phage display. This wild type nanobody was taken as a reference and mutated 
at critical amino acids interacting with EGFR, their free energies were calculated by in 
silico steered molecular dynamics, where the nanobody was pulled away from the ligand 
and the force applied was calculated. For modelling the nanobody- ligand interaction 
dynamic properties, root mean square deviation was calculated for each mutated 
candidate. After all tests, the best binding nanobody was selected tested by in vitro 
binding assays (Farasat et al. 2016). 
 
 
1.5.3.   Uses of Nanobodies 
 
Nanobodies are advantageous due to their size, stability and ease of production. Primarily 
nanobodies are used as a research tools. For real-time and live-cell imaging in order to 
visualize intracellular molecules, nanobodies can be expressed, fused to green or red 
fluorescent proteins. These intracellular fluorescently tagged reagents were trademarked 
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as Chromobodies® which were generated by the Chromotek® company (Rothbauer et 
al. 2006). They can be expressed in cells by transfection of encoding plasmids or in stable 
cell lines and interact with the target without interfering with their cellular function. Due 
to their high specificity, they can provide superresolution images showing single- 
molecule localization. Also, they do not form aggregations inside the cell and they can 
track important components of the cell cycle with no effect on the process and viability 
(Rothbauer et al. 2006). In addition to intracellular protein targeting, nanobodies can also 
target GFP (Kubala et al. 2010) which is an fluorescent molecule that has been used to 
tag numerous endogenous proteins. 
 
One application of nanobodies are in the mammalian two hybrid system that is used to 
detect protein- protein interactions. In this system there is a GFP tagged bait protein and 
mCherry tagged prey protein, when GFP nanobody is also expressed in cells, it binds to 
the GFP tagged bait protein, localizing it to specific foci. With this system both 
localization of bait and prey proteins can be observed. Moreover the activity of inhibitors 
of this molecular interaction can be monitored (Beghein and Gettemans 2017). For 
molecular imaging, nanobodies should not interfere with the function of the target 
protein. However, in order to explore a protein function, nanobodies interfering with its 
function can be used. In other words, it can be used as inhibitors (Newnham et al. 2015). 
Also, nanobodies can be used in protein purification and immunoprecipitation 
experiments. Because they are stable and monomeric, they can be easily immobilized to 
solid surfaces (Meyer, Muyldermans, and Depicker 2014). They can also be used for 
chromatin immunoprecipitation together with DNA microarrays (Nguyen-Duc et al. 
2013) or for structural biology purposes like crystallization. They can stabilize dynamic 
proteins in a preferred confirmation or they can help the crystallization of detergent- 
solubilized membrane proteins (Koide 2009). 
 
Secondly, nanobodies can be used as diagnostic tools. In order to use nanobodies in 
detection systems, there are several important points. When nanobodies are coated on 
plates for ELISA experiments, due to their small size they may not be exposed for antigen 
binding so C-terminal peptide extensions must be used (Harmsen and Fijten 2012). 
Because they are highly stable and can withstand to harsh regeneration conditions, they 
can be used in surface plasmon resonance based detection systems (Saerens et al. 2008). 
Some studies show that nanobodies can be used for pathogen diagnosis. There are 
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nanobodies which can distinguish Brucella from a similar pathogen called Yersinia. 
Nanobodies can pave the way for solving important health problems; used as diagnostic 
tools they can help identify the best antigens for vaccine development (Abbady et al. 
2012). Also, for HIV diagnosis p24-VHH fusions were generated which can be used to 
detect the HIV antigen in the serum by its ability to cause agglutination (Habib et al. 
2013).  
 
Nanobodies can also be used for diagnostic imaging. Diagnostic imaging tracers used 
should have low background signals, high stability and solubility and low 
immunogenicity (Meyer, Muyldermans, and Depicker 2014). Full length of antibodies 
labelled with radionuclides are used as tracers but they have high serum half- life and low 
ratio of tumor to background signal which is not suitable for imaging purposes. 
Nanobodies, on the other hand, can penetrate tumor easily due to their small size and 
unbound nanobodies can be rapidly cleared from the body which enables high tumor to 
background signaling. Also, they can reach to target tissue in a few hours so this enables 
the use of short-lived radio nucleotides which are better to reduce side effects suffered by 
patients (Vaneycken et al. 2011). In addition to their use as diagnostic imaging tracers, 
nanobodies can be used for diagnostic cancer tests. For example, for prostate cancer, 
nanobodies detecting different isoforms of prostate- specific antigen (PSA) in the blood 
circulation were generated (Mikolajczyk et al. 2004). Nanobodies designed in a way that, 
they can easily discriminate between different isoforms and change conformation 
according to it. This is important for giving information about stages of the prostate 
cancer (Saerens et al. 2004). 
 
Thirdly, nanobodies can be used as therapeutic agents. There are lots of studies about 
generating nanobodies against scorpion toxins, bacterial toxins and snake venom. 
Nanobodies are very suitable for these purposes since they can recognize special epitopes 
(Hmila et al. 2010). They can reach hidden epitopes which cannot be reached via 
conventional antibodies so this is an important advantage when considering nanobodies 
as therapeutic agents. Another advantage is, nanobodies are stable and they have high 
tumor penetration, they can be used for targeting tumor antigens (Conrath et al. 2001). 
For cancer therapy, there are lots of different nanobodies targeting growth factor 
receptors, death receptors and chemokine receptors. For example, targeting epidermal 
growth factor receptor (EGFR) is a commonly used target (Bruin et al. 2014), also 
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nanobodies can target human epidermal growth factor (HER2) (Rahimi et al. 2012). 
Another target for cancer therapy can be DR5 which is a death receptor (Huet et al. 2014). 
In addition to these, nanobodies can be used for the delivery of nanoparticles. There are 
several ways for the delivery of these nanoparticles like liposomes, micelles and polymer-
based polymersomes (Bannas, Hambach, and Koch-Nolte 2017). For drug delivery there 
are some problems like poor solubility, stability, immunogenicity and rapid clearance 
from the body (Audenhove and Gettemans 2016). Addition of nanobodies on these 
nanoparticles can increase the stability, specificity and decrease the immunogenicity 
(Sapra and Allen 2003). Another example for the use of nanobody as therapeutic agent 
are CAR (Chimeric antigen receptor) expressed in T lymphocytes and natural killer (NK) 
cells. This system includes a single- chain fragment variable domain of an antibody 
specific to a target and a T cell receptor signaling domain (Maus et al. 2019). However 
single chain variable antibodies are not that stable, so the use of nanobodies as the antigen 
recognition component may be a good option for generating CAR expressing T/NK cells 
(Bannas, Hambach, and Koch-Nolte 2017). 
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2. AIM OF THE STUDY 
 
 
 
p53 is an important tumor suppressor protein which has vital roles such as cell cycle 
arrest, senescence and apoptosis. The regulation of the p53 protein is provided by MDM2 
and MDM4 proteins which are negative regulators of p53. In most cancers, either there 
is a mutation in p53 or an overexpression of its negative regulators. In this context, 
identification of inhibitors of the p53 inhibitory MDM2/ MDM4 proteins to activate p53 
for targeting tumor cell death is an attractive alternative to other chemotherapeutics. For 
some cancers the use of MDM2 inhibitors are not enough to activate p53 so MDM4 
inhibitors are needed. In this project, we used in silico designed nanobodies, which are 
single chain variable domain antibodies, as inhibitors of the interaction between p53 and 
the MDM4 protein. We optimized the purification of these nanobody proteins and tested 
their binding affinities against the MDM4 protein by surface plasmon resonance and the 
fluorescent two hybrid (F2H) assay.  
 
In the first part of the project, we aimed to optimize nanobody purification. For 
periplasmic expression, we used the pET22b plasmid and the Rosetta 2 DE3 pLYSs 
bacterial expression strain. We tried osmotic pressure and whole cell lysis protocols to 
purify these proteins. On the other hand, for cytoplasmic expression, we generated 
sulfhydryl oxidase expressing BL21 DE3 cells and used the pET28a plasmid to express 
nanobodies in the cytoplasm.  
 
In the second part of the project, we tested the affinity of purified anti-MDM4 nanobodies 
by surface plasmon resonance and compared their binding affinities of different 
nanobodies to p53 binding domain of MDM4 protein. In the third part of the project, we 
optimized fluorescent two hybrid (F2H) assay to show the interaction of selected 
nanobodies with the MDM4 protein. We used Baby Hamster Kidney cells (BHK) cells 
for this system. Both p53 and the p53 binding domain of the MDM4 proteins were tagged 
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with fluorescent proteins which co-localized to overlapping foci in the nuclei of these 
cells. The presence of an MDM4 binding nanobody resulted in the inhibition of the co-
localization and was used to estimate the affinity of these nanobodies against the MDM4 
protein. In summary, we aimed to optimize nanobody purification and test their binding 
using two different methods in order to explore novel nanobodies which can be used as 
therapeutics for cancers with over expressed MDM4 protein. 
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3.   MATERIAL & METHODS 
 
 
 
3.1.   Materials 
 
 
3.1.1.   Chemicals 
 
All the chemicals used in this thesis is shown in Appendix A. 
 
 
3.1.2.   Equipment  
 
All the equipment used in this thesis is shown in Appendix B. 
 
 
3.1.3.   Solutions and Buffers  
 
Calcium Chloride (CaCl2) solution: 60 mM CaCl2, 15% glycerol and 10mM PIPES (pH 
7.0) were mixed. Mixture is completed to 500 ml with ddH2O. The solution was sterilized 
with filter (0.22 µM) and stored at 4°C.  
Agarose Gel: For 100 ml 1% w/v agarose gel, 1g of agarose powder is dissolved in 100 
ml 0.5XTBE buffer with the help of heating in a microwave. 
Tris-Borate-EDTA (TBE) Buffer: To prepare 1L 5X stock solution, 54g Tris-Base, 27.5g 
boric acid, and 20 ml 0.5M EDTA pH 8.0 were dissolved in ddH2O and stored at room 
temperature. 
Phosphate-Buffered Saline (PBS): For 1 L 1X solution, 100 ml 10X PBS was mixed with 
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900 ml ddH2O. The solution was sterilized with filter (0.22 µM). 
Polyethyleneimine (PEI) Solution: To prepare working solution of 1 mg/ml (w/v), 100 
mg polyethyleneimine powder was dissolved in 100 ml of ddH2O. The pH was adjusted 
to 7.0 with 33% HCl. Then, filter- sterilized solution was kept at -20°C.  
SDS Separating Gel: To prepare 10 ml 10% separation gel, 2.5mL 1.5M Tris pH 8.3, 
3.34ml Acrylamide: Bisacrylamide (37.5:1), 100 µl 10% (w/v) SDS, 100 µl 10% (w/v) 
APS and 10 µl TEMED was mixed and completed to 10 ml with ddH2O. 
SDS Stacking Gel: For 5 ml 4% stacking gel, 1.25 ml 0.5 M Tris pH 6.8, 50 µl 10% SDS 
(w/v), 1 ml Acrylamide: Bisacrylamide (37.5:1), 15 µl 10% APS (w/v), and 7.5 µl 
TEMED were mixed and completed to 5 ml with ddH2O.  
Tris-Glycine Solution: To prepare 1 L 10X stock solution, 40 g Tris base and 144 g 
Glycine were dissolved in ddH2O and pH was adjusted to 8.3. 
SDS Running Buffer: 100 ml of 10X Tris-Glycine was mixed with 895 ml dH2O and 5 
ml of 20%(w/v) SDS.  
Protein Loading Buffer: To prepare 4X protein loading buffer, 2.4 mL Tris from 1 M pH 
6.8 stock, 0.8 g SDS, 4 ml glycerol (100%), 0.01% bromophenol blue, and 2 ml β-
mercaptoethanol were mixed and was completed to 10 ml.  
Lysis Buffer: In order to prepare 50 ml 1X lysis buffer, 50 mM HEPES, 250 mM NaCl, 
0.5 mM TCEP, 10 mM imidazole, EDTA-free protease inhibitor cocktail (Roche) and 10 
µl DNase I (100U/ µl) were mixed and completed to 50 ml with ddH2O.  
Cell resuspension buffer for Osmotic Shock: 0.5 M sucrose, 0.2 M Tris pH 8 and 0.5 mM 
EDTA was mixed and kept in 4°C. 
Tris- Sucrose- EDTA (TSE) buffer: This buffer was used for osmotic shock. 200 mM 
Tris-HCl at pH 8, 500 Mm sucrose and 1 mM EDTA were mixed with EDTA-free 
protease inhibitor cocktail (Roche). For 10 ml of TSE buffer, 1 tablet of EDTA-free 
protease inhibitor cocktail was used. Protease inhibitor should be added freshly to TSE 
buffer. 
 26 
Buffer IMAC-A: To prepare 1L of IMAC-A solution, 50 mM HEPES, 250 mM NaCl, 
and 10 mM imidazole were mixed and completed to 1 L with ddH2O. The solution was 
filter-sterilized kept at 4°C. 0.5 mM TCEP was added before using the solution freshly.  
Buffer IMAC-B: 50 mM HEPES, 250 mM NaCl, and imidazole were mixed and filter-
sterilized. Imidazole amount is added according to the need. 0.5 mM TCEP was added 
before using the solution freshly. This solution was used as the elution buffer of His-
tagged affinity chromatography. Elution buffer with 50 mM, 100 mM, 300 mM, and 600 
mM imidazole concentrations were used.  
 
3.1.4.   Growth Media 
Luria Broth (LB):   For 1 L 1X LB medium, 20 g LB powder was completed to 1 L with 
ddH2O and autoclaved at 121°C for 15 minutes. For antibiotic selection, final 
concentrations of antibiotics were; kanamycin 50 µg/ml, ampicillin 100 µg/ml and 
chloramphenicol 34 µg/ml.  
LB Agar: For 1 L 1X LB-agar medium, 35 g LB-Agar powder was completed to 1L with 
ddH2O and autoclaved at 121°C for 15 minutes. The antibiotic was added after cooling 
down. For antibiotic selection, final concentrations of antibiotics were; kanamycin 50 
µg/ml, ampicillin 100 µg/ml and chloramphenicol 34 µg/ml. 15 ml of LB-Agar solution 
was poured into a sterile petri dish under bacteria hood and plates were kept at 4°C.  
DMEM: BHK cells were maintained in culture in DMEM growth medium containing 
10% heat-inactivated fetal bovine serum (FBS) and1% PenStrep containing 100 U/mL 
Penicillin and 100 µg/mL Streptomycin.  
Freezing Medium: Heat-inactivated fetal bovine serum containing 10% DMSO (v/v) was 
used for freezing cells. 
Terrific Broth (TB): For 1 L 1X TB medium, 47.6 g TB powder and 8 ml glycerol was 
mixed, and completed to 1 L with ddH2O. The mixture was autoclaved at 121°C for 15 
minutes.  For antibiotic selection, final concentrations of antibiotics were; kanamycin 50 
µg/ml, ampicillin 100 µg/ml and chloramphenicol 34 µg/ml. 
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3.1.5.   Molecular Biology Kits    
All the molecular biology kits used are shown in Appendix C.  
 
3.1.6.   Enzymes 
All the enzymes; restriction and modifying enzymes, polymerases and their buffers and 
PCR reaction ingredients were obtained from New England Biolabs (NEB). 
 
3.1.7.   Bacterial Strains 
Escherichia coli (E. coli) DH-5α is used for general cloning applications and E. coli 
Rosetta 2 DE3, Rosetta 2 DE3 pLysS and BL21 DE3 expression strains were used for 
nanobody production and purification.  
 
3.1.8.   Mammalian Cell Lines  
BHK: BHK21 cell line was derived from the kidneys of Syrian hamsters and the cell line 
we used has Lac operator repeats in their genome. 
 
3.1.9.   Plasmid and Oligonucleotides 
All the plasmids and oligonucleotides used are shown in Table 3.1 and 3.2 respectively. 
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Table 3.1 List of plasmids 
PLASMID NAME PURPOSE OF USE SOURCE 
pET22b Bacterial expression 
plasmid for nanobody 
expression in periplasm 
 
pET28a Bacterial expression 
plasmid for cytoplasmic 
expression 
Lab Construct 
SOX plasmid Sulfhydryl oxidase Kindly gifted from Ario de 
Marco 
pCDNA3.1/ myc- His (-) 
B 
Mammalian expression 
plasmid with CMV 
promoter 
Thermo Fischer Scientific, 
(V85520) 
pCDNA3- GFP Positive control for F2H 
assay, GFP expressing 
plasmid  
Lab Construct 
Pet47 b  Bacterial expression 
plasmid for MDM4 
plasmid  
Lab Construct 
 
 
 
 
 
 
 29 
Table 3.2 List of oligonucleotides 
 
 
OLIGONUCLEOTIDES 
 
 
        
 
SEQUENCE 
 
PURPOSE 
OF USE 
MDM4 Nb and MDM4 
CDR3 Nb XhoI Forward 
ATTCCTCGAGAATGGAAGTGCAGCT 
GCTGGAAAGC 
Cloning for  
F2H assay 
MDM4 Nb and MDM4 
CDR3 Nb Reverse 
ACCACTTCCACCGCCTCCAGAACCTC 
CTCCACCTAAGCTTCTCGCGCTGCTCA 
CGGTCAA 
Cloning for 
F2H assay 
Linker Forward GGCGGTGGAAGTGGTGGCGGAGGTA 
GCGGTGGAGGAGGTTCTATGAGCGAG 
CTGATTAAGGAGAAC 
Cloning for 
F2H assay 
BFP BamHI Reverse TGCTTAGGATCCTCAATTAAGCTTGTG 
CCCCAGTTTG 
Cloning for 
F2H assay 
GFP CDR3 Nb Forward ATTCCTCGAGAATGTTTGTGCAGCTGG 
TGGAAAGC 
Cloning for 
F2H assay 
GFP CDR3 Nb Reverse ACCACTTCCACCGCCTCCAGAACCTCC 
TCCACCTAAGCTTCTTTTGCTGCTCACG 
GTCACCT 
Cloning for 
F2H assay 
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3.1.10.   DNA and Protein Molecular Weight Markers 
DNA ladder and protein ladder which were used is shown in Appendix E. 
 
3.1.11.   DNA Sequencing 
DNA sequencing analysis was provided by McLAB, CA, USA. 
(https://www.mclab.com/home.php)  
 
3.1.12.   Software, Computer-based Programs, and Websites 
Software, computer-based programs and websites used are shown in Table 3.3. 
Table 3.3 List of software and computer-based programs and websites 
SOFTWARE, 
PROGRAM, WEBSITE 
NAME 
COMPANY/WEBSITE PURPOSE OF USE 
CLC Main Workbench 
v7.9.4 
QIAGEN Bioinformatics Cloning, primer design, 
sequence analysis and 
alignment 
NCBI BLAST https://blast.ncbi.nlm.nih.gov Alignment tool 
Addgene https://www.addgene.org Plasmid map information 
ExPASy https://www.expasy.org Protein translation and 
parameter tool 
BIACORE T200 software 
v3.0 
GE Healthcare Life Sciences  Controlling and evaluating 
SPR experiments 
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3.2.  Methods 
 
 
3.2.1.   Bacterial Cell Culture 
 
3.2.1.1.   The growth of Bacterial Culture           
 
E.coli DH5α, Rosetta DE3, Rosetta DE3 pLYSs strains were cultured in LB with 
antibiotics for selection, overnight around 12-16 hours at 37 °C with vigorous shaking 
(221 rpm). In order to get single bacterial colony, the culture was spread via autoclaved 
glass beads onto LB-Agar plate including the antibiotics for selection and plates 
incubated overnight at 37 °C. For glycerol stock preparation, 10% (v/v) glycerol is added 
to the bacterial culture for 1 ml final volume under hood. Cryovials were used for glycerol 
stocks and they are stored at -80 °C.  
 
3.2.1.2.   Preparation of competent bacteria 
Competent E. coli DH5α was added into 40 ml LB in a 250 flask without any antibiotics 
because it has no resistance and incubated overnight at 37 °C with shaking at 221 RPM. 
Next day, 4 ml of overnight- grown culture was taken from 40 ml culture and put into 
400 ml LB in 2L flask. In this step optical density (OD) was checked and when OD590nm 
reached to 0.375 incubation was stopped. 400 ml culture was separated into 8 50 ml tubes 
and they are incubated on ice for 10 min. Then, they were centrifuged at 1600xg for 10 
min at 4°C. Supernatant were removed and pellets were resuspended in 10 ml ice-cold 
CaCl2 solution. Cells were incubated on ice for 30 min. After incubation, cells were 
centrifuged at 1100 xg for 5 min at 4°C. Supernatant was removed and pellet was 
resuspended in 2 ml ice- cold CaCl2 solution. All the suspensions were put together in 50 
ml tube and separated into 200 µl aliquots. Aliquots were put into pre-chilled 
microcentrifuge tubes and flash- frozen in liquid nitrogen at -80 °C. Their transformation 
efficiency was checked by transforming pUC19 plasmid. The same protocol was applied 
for preparation of Rosetta 2 DE3, Rosetta 2 DE3 pLYSs, BL21 competent bacteria. 
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3.2.1.3.   Transformation of competent bacteria 
Flash frozen aliquots of bacteria were thawed on ice until it became viscous. Then 
plasmid with the desired concentration was added on the bacteria and incubated on ice 
for 30 min. After ice incubation, cells were heat shocked at 42 °C for 90 sec and put into 
ice for 2 min. 800 µl of LB was added and bacteria incubated in 37 °C for 45 min. After 
45 min, cells were centrifuged at 13,200 rpm for 30 sec and after supernatant was 
removed, pellet was resuspended in 100 µl of LB and spread onto agar plate containing 
antibiotics and plates were incubated at 37 °C overnight. 
 
3.2.1.4.   Plasmid DNA Isolation  
For isolation of plasmid DNA from E.coli DH5α, alkaline lysis protocol from Molecular 
Cloning: A Laboratory Manual (Sambrook et al.) was used. For midiprep, Macherey 
Nagel Midiprep kit was used. The acquired plasmid DNA concentration and purity 
analyzed by a Nanodrop spectrophotometer. 
 
3.2.2.   Mammalian Cell Culture    
 
3.2.2.1.   Maintenance of Cell Lines 
BHK cells were maintained in complete DMEM medium in sterile 10 cm tissue culture 
plates and incubated in incubator which is set to 37 °C and 5% CO2. Cells were split after 
they reached 70-80% confluency. In order to split cells, first cells were washed with 
serum-free DMEM and trypsin was added afterwards. Cells waited in trypsin 5 min inside 
incubator which is set to 37 °C and 5% CO2. Then, cells were suspended in complete 
DMEM and split to a new sterile 10 cm tissue plate at 1:10 ratio. Splitting should be done 
every 2-3 days. 
3.2.2.2.   Cryopreservation of cells 
Cells were split to become 30-40% confluent one day before freezing. Next day, cells 
were counted and 1-5x 106 cells were centrifuged at 300x g for 5 min. Pellet was 
resuspended in 1ml freezing medium and put into a cryovial tubes. Cryovials put into a 
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freezing container containing isopropanol and placed into -80 °C fridge. Cryovials were 
transferred to the liquid nitrogen for long term storage.  
 
3.2.2.3.   Thawing of frozen mammalian cells 
Cryovials inside nitrogen tank were taken out and quickly thawed by adding 9 ml DMEM. 
Cells were centrifuged at 300x g for 5 min to get rid of DMSO. Supernatant was removed 
and pellet was resuspended with 10 ml complete DMEM inside 10 cm tissue culture plate 
and incubated at 37 °C and 5% CO2. Next day, medium was changed to fresh one. 
 
3.2.2.4.   Transient Transfection of Mammalian Cell Lines Using Polyethyleneimine 
(PEI) 
One day before transfection, desired number of cells were seeded according to plate type. 
Next day, for transfection, the required amount of DNA was mixed with 200 µl serum-
free phenol red- free DMEM in a sterile microcentrifuge tube. PEI (1µg/µl) was vortexed 
well and added to DNA- DMEM mix (the ratio of PEI to DNA should be 3:1). The 
mixture was vortexed immediately after addition of PEI and incubated at room 
temperature 15 min. The mixture was added drop wise on top of cells. The summary of 
ingredients of PEI transfection in 6 well plate and their amounts shown in Table 3.4. 
Table 3.4 List of ingredients used in PEI transfection in 6 well plate.  
Cell number  
seeded 
2.5x 105 
 
DMEM amount in 
which cells were 
seeded 
2 ml 
 
Total DNA amount 3 µg 
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The DMEM Amount 
in which transfection 
was performed 
200 µl 
PEI: DNA ratio 1:3 
 
  
3.2.3.   Vector Construction 
Restriction enzyme digestion 
Template DNA, enzymes, and its buffer was incubated for 30 min to 2 h at optimum 
temperature depending on the enzyme. After digestion, DNA was run on an agarose gel 
for cloning. 
Dephosphorylation of 5’ phosphate groups 
 In order to remove 5’ phosphate groups, which will prevent circulation of vector after 
digestion, alkaline phosphatase enzyme (calf intestinal alkaline phosphatase, CIP) was 
used. 
Agarose gel electrophoresis and DNA purification from the gel 
CIP added vector or digested vector was run on gel. Based on the DNA fragment size, 0.7-
2 % agarose gels were prepared with 100 ml of 0.5X TBE solution and then heated with 
microwave. After gel was heated, it was cooled and 0.0002% ethidium bromide was added 
and mixed well. 10 minutes later when gel was solidified, DNA samples were loaded and 
run at a constant voltage 100 V. In order to get the digested vector, gel extraction was 
carried out by cutting the DNA band from the gel. 
Ligation 
100 ng vector was used for ligation reactions with required amount of insert. Control gel 
with same volumes of both vector and insert can be prepared to see the ratio difference 
between them. After determining the ratio, ligation reaction with 1:3 vector to insert ratio 
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was prepared. The ligation reaction incubated at 16 °C overnight. Next day, ligation 
product was transformed to competent E.coli  DH5α.  
 
3.2.4.   Protein Purification 
3.2.4.1.   Vector Construction 
For cytoplasmic expression of nanobodies pET-28a (+) bacterial expression vector was 
used. The vector has C- terminal His-tag. Nanobody DNA sequences were obtained from 
pET-22 b (+) vector via digestion with NcoI and NotI. Also pET-28a (+) was digested 
with the same enzymes. Both enzymes worked at 37 °C and digested for 1 h. After 
digestion gel extraction was carried out and digested inserts which are Fersht original, 
Fersht CDR3 optimized, Fersht CDR1 CDR3 optimized, GFP original and GFP CDR3 
nanobody DNA sequences, and digested pET-28a (+) was obtained.  Before ligation via 
control gel, concentrations of each insert and vector were decided. Vector and inserts 
ligated with 1:3 ratio and ligation reaction incubated at 16 °C overnight. Ligation products 
were transformed to DH5α. Next day, single bacterial colonies were picked and their 
pDNAs were isolated. In order to confirm whether ligations worked or not, diagnostic 
digestion with known cut sites were carried out. 
Table 3.5 List of ingredients for pET-28a (+) digestion 
 Insert pET-28a (+) 
DNA 2 µg 2 µg 
CutSmart Buffer (NEB) 5 µl 3 µl 
NcoI 1 µl 1 µl 
NotI 1 µl 1 µl 
ddH2O To 50 µl To 30 µl 
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3.2.4.2.   His-tagged protein expression 
For periplasmic expression, pET-22b (+) plasmid was used and plasmid contains all the 
features for protein expression and purification; T7 promoter, lac operator, LacI gene, N-
terminal pelB sequence, C-terminal His-tag and finally ampicillin resistance gene for 
selection. LacI normally binds to lac operator and blocks the transcription of protein from 
T7 promoter; after IPTG was added to the medium, it competes with LacI. With the help 
of removing the blockage, protein can be expressed. N-terminal His- tag was needed for 
affinity chromatography and N-terminal pelB sequence was needed to send the protein to 
periplasmic space where disulfide bonds can be formed. pET-22b (+) plasmid with 
nanobody sequences were transformed to both Rosetta 2 DE3 and Rosetta 2 DE3 pLYSs. 
Rosetta 2 DE3 strains are derivative of BL21 strain and designed to express eukaryotic 
proteins which contains rarely used codons in bacteria. These strains have extra tRNAs 
for rare codons and backbone of this rare tRNA coding vector has chloramphenicol 
resistance gene. DE3, on the other hand, shows that the strain is a lysogen of λDE3 which 
means a prophage presents as DNA expressing T7 RNA polymerase gene under the 
control of the lacUV5 promoter and protein production is controlled via IPTG. pLYSs 
strains produces T7 lysozyme and this system provides controlled protein production by 
preventing basal expression of T7 RNA polymerase and reduces the leakage in protein 
production.  
For both expression and purification of the proteins, many methods were tried with 
variations.  In the first trials, different osmotic pressure protocols were tried for 
periplasmic protein expression and purification. It generally includes, addition of Tris-
Sucrose- EDTA buffer to pellet and addition of water to provide osmotic pressure which 
will cause shrinkage of cytoplasm and periplasmic contents were released to 
environment. After several trial, it was decided to check more than one colonies to see 
whether they are all producing the same nanobody in the same concentration. After 
transformation of, pET-22b (+) vectors to both Rosetta 2 DE3 and Rosetta 2 DE3 pLYSs 
for periplasmic protein purification several colonies were picked and inoculated into 3 ml 
LB containing both ampicillin and chloramphenicol.  After incubation of 3 ml pre-
cultures at 37 °C for 16 h 221 rpm then they were transferred to 100 ml cultures containing 
40% of general ampicillin and chloramphenicol concentrations. 100 ml culture was 
incubated at 37 °C 221 rpm until optical density at 600 nm reaches to 0.6. After cultures 
reached to the desired optical density, cultures were incubated on ice and 0.5 mM final 
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concentration of IPTG added. Protein induction was performed by incubating the culture 
at 18 °C overnight in shaker incubator with 180 rpm (Figure 3.1). For negative control 
one culture may not be induced with IPTG.  
 
Figure 3.1 Periplasmic protein expression and induction. 
 
On the other hand, for cytoplasmic expression pET-28a plasmid construct was used and 
it is transformed into competent BL21 DE3 strain containing SOX plasmid (Nguyen et 
al. 2011) Different from other methods, arabinose is added prior to induction with IPTG 
because disulfide bond forming enzymes is under the control of the arabinose promoter. 
A colony was picked from the plate and put into 5ml LB containing chloramphenicol and 
kanamycin and incubated overnight at 30 °C 200 rpm. Next day, 5 ml culture was 
transferred to 50 ml LB containing chloramphenicol and kanamycin and incubated 
overnight at 30 °C 200 rpm. After incubation, 50 ml culture was put in 1 L LB culture 
with the same antibiotics. The culture was left in incubator at 30 °C 200 rpm for a while 
and optical density was checked to reach 0.4. 0.5% w/v arabinose was added after the 
culture reached to 0.4 optical density and incubated at 30°C 200 rpm for 30 min. 0.5 mM 
IPTG was added and culture was induced for 4 h at 30°C 200 rpm (Figure 3.2). 
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Figure 3.2 Cytoplasmic protein expression and induction. 
 
3.2.4.3.   Affinity chromatography of His tagged proteins 
For periplasmic protein purification, there are three main protocols applied. First protocol 
which is based on osmotic pressure application to induced cultures was used (McMahon 
et al. 2018). Next day after induction, cells were pelleted at 3500 g 15 min at 4 °C and 
cells were resuspended in 100 ml cold 0.5 M sucrose, 0.2 M Tris pH8 and 0.5 mM EDTA. 
Cells incubated on ice 5 min and cold 200 ml water was added. 300 ml culture was put 
into 500 ml flask and with a magnetic stirrer, it was mixed 45 min. This step is important 
because it will release the periplasmic content. On top of the lysate, NaCl, MgCl2 and 
imidazole was added as the final concentrations were 150 Mm NaCl, 2 Mm MgCl2 and 
20 Mm imidazole. The mixture was centrifuged at 20.000 g for 20 min at 4 °C (Figure 
3.3). In order to see the protein presence in the soluble part, SDS-PAGE was carried out 
and afterwards according to situation, His Tag protein purification protocol was applied.  
 
Figure 3.3 First osmotic shock lysis protocol. 
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Second protocol was also based on osmotic shock application (Quan et al. 2013). After 
induction, next day, 100 ml bacterial cultures were harvested by centrifugation at 3,000xg 
for 20 min at 4°C. Supernatants were removed and pellets were resuspended with 1 ml 
TSE buffer and they were incubated on ice for 15 min. 2 ml cold water was added on top 
of TSE buffer and pellet mixture. Suspensions were transferred to microcentrifuge tubes 
and centrifuged at 16,000 xg for 30 min at 4 oC.  Supernatants which were containing 
periplasmic protein contents was transferred into new microcentrifuge tubes. In order to 
screen the contents of periplasms of different colonies, SDS- PAGE was carried out 
(Figure 3.4). After SDS- PAGE, positive colonies which are producing nanobodies were 
selected and the same protocol was applied with higher culture amounts. After 3 ml pre 
culture, the culture was transferred to 50 ml culture instead of 100 ml and afterwards it 
was transferred to 1 L culture and whole procedure was repeated.  
 
Figure 3.4 Second osmotic shock lysis protocol. 
 
Third protocol tried for periplasmic expression was general whole cell lysis His tag 
protein purification protocol used our laboratory.  Before preparing large cultures, for this 
one again colony screening was carried out with 3 ml precultures and induced 25 ml 
cultures. After that, using positive colonies large scale protein expression and purification 
was carried out. For large scale 1L culture and whole cell lysis, cells were harvested at 
4000 rpm 10 min. Supernatant was removed and pellet was dissolved in 25 ml of lysis 
buffer for 1 L culture pellet. The cells were lysed at 4°C in a box full of ice by sonication 
using Qsonica Q500. Sonication was carried out at 5 seconds on and 10 seconds off with 
total elapsed time 6 min and 30 sec was used (Figure 3.5). The cell lysate was then 
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centrifuged at 15,000 rpm 45 min at 4°C. Samples for SDS-PAGE was taken from both 
pellet and supernatant.  
 
Figure 3.5 Nanobody purification with protocol whole cell lysis protocol. 
 
The steps after applying supernatants to column are the same for both osmotic pressure 
protocols and whole cell lysis protocol. After supernatant which will be loaded to column 
was prepared, the column was washed with ddH2O. For 1L culture lysate, 3 ml HisPur 
Cobalt Superflow Agarose was added on to column. Since the resin solution was diluted 
1:1 in EtOH, 1.5 ml actual resin was added. After column is loaded with resin, it was 
equilibrated and washed with ddH2O. After water was removed, 10 ml IMAC-A buffer 
was used 2 times washing. Supernatant which was coming from osmotic pressure 
protocol or whole cell lysis protocol was poured into column and resin-protein mixture 
was incubated with end- to-end rotation for 30 min at 4 °C. Flow through was collected 
after incubation in 50 ml tube. This fraction contains proteins which did not have His-tag. 
Then, resin and protein mixture in the column was washed with 10 ml IMAC A 3 times. 
For elution of the nanobodies, IMAC-B solutions with different imidazole concentrations 
were used. Starting from lowest concentration of imidazole, IMAC-B solutions were 
applied to column and fractions were collected in 15 ml tubes 4 °C (Figure 3.6).  
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Figure 3.6 His-tag nanobody purification with cobalt resin column. 
 
3.2.4.4.   Purification of His-Tagged proteins by Batch Method 
After His Tag protein expression and osmotic pressure application, Batch method were 
also used for some nanobodies. Whole procedure was carried out in 4 °C. Required 
amount of Cobalt Superflow Resin inside 15 ml falcon were put and centrifuged for 2 
minutes at 700 xg to get rid of ethanol. 2 resin bed volumes of equilibration buffer which 
is IMAC A was added and mixed until the resin is fully resuspended. By centrifuge for 2 
min at 700 xg buffer was removed. The supernatant containing His tag proteins, was 
mixed with IMAC A buffer to a volume greater than or equal to the resin bed volume. 
The mixture of supernatant and IMAC A was added on the tube with resin and mixed 
slowly for 30 min. After centrifuge for 2 min at 700x g, supernatant was removed. Resin 
was washed with two resin bed volumes of IMAC A. Again after centrifuge with the same 
conditions, supernatant was removed. This washing step was repeated 3 times. Elution 
step was carried out by addition of IMAC D buffer on the resin and mixture was rotated 
10 min. After that by centrifuge for 2 min at 700 g, supernatant was removed and elution 
steps were repeated 2-4 times and each fraction was separated into different tubes. The 
content of fractions was checked via SDS-PAGE. 
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3.2.4.5.   SDS-PAGE gel and Coomassie Blue Staining 
14% separating gel and 4% stacking gel were prepared and the samples from each step 
of protein purification, cell lysate after sonication, pellet, non-retained fraction and elutes 
were mixed with 4X protein loading buffer and denatured at 95 °C for 10 min. After the 
samples were loaded, it was run with 1X running buffer for 2- 2.5 h. The gel was separated 
from the glasses after the run. The stacking part of the gel was discarded and separating 
part of the gel was stained with Coomassie blue with the help of heating via microwave 
with the staining solution prior to incubation overnight. 
 
3.2.5.   Surface Plasmon Resonance 
BIACORE T200 was used for surface plasmon resonance (SPR) experiments. SPR is a 
method for investigating quantitative protein- protein interactions and kinetic parameters 
of these protein interactions. This method is basically uses the change in refractive indices 
when polarized light hits a gold film. There is light source and via prism light is focused 
on the gold film and reflected light is collected with a detector (Figure 3.7). The system 
relies on change in refractive index of medium at the interface and it depends on the mass 
attached to gold surface. According to mass change on the surface, refractive index is 
changing proportionally and some part the light is absorbed. This gives information about 
the quantification of the binding occurs on the surface as resonance unit (RU). 
 In this method, ligand is the attached molecule on the gold surface and analyte is the 
molecule in mobile phase which is flowing on the surface of the chip with running buffer. 
There are several steps to follow such as, pH scouting and immobilization of the ligand 
on the surface, injection of ligand and regeneration of the surface. In this study, p53 
binding domain of MDM4 was immobilized covalently on Sensor Chip CM5. CM- series 
sensor chips carry a matrix of carboxymethylated dextran attached to gold surface.  The 
ligand, which is p53 binding domain of MDM4, was covalently attached to sensor surface 
via amine coupling. For immobilization, initially, surface of the gold chip should be 
activated. For activation, mixture of 1-ethyl-3- (3- dimethylaminopropyl) carbodiimide 
(EDC) and N- hydroxysuccinimide (NHS) was used. When EDC and NHS was passed 
on the surface, it reacted with carboxyl groups of the dextran and formed succinimide 
esters. This reactive ester groups interact with amino groups of ligand and formed 
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covalent bonds between dextran surface and ligand. For this reaction to be successful, 
electrostatic interaction between ligand and dextran should be strong. The dextran matrix 
has negative charge at pH values above 3.5. The matrix should have negative charge and 
ligand should have positive charge so isoelectric point of the ligand should also be 
considered. To provide this, the pH of immobilization buffer which is acetate buffer 
should be above 3.5 and below the isoelectric point of the ligand. In order to decide the 
pH of acetate buffer for coupling, pH scouting was carried out. Different acetate buffers 
were used such as pH 4, 4.5, 5 and 5.5 and the interaction with the surface and ligand was 
compared by examining the RU differences.  
After pH scouting, immobilization with the decided acetate buffer was performed and 
deactivation of unbound surface was done with ethanolamine with pH 8.5. In the second 
step, different concentrations of analyte, which was MDM4 Nb, MDM4 CDR3 Nb and 
GFP Nb, passed on the surface separately. Dilutions for nanobodies was prepared with 
HBS-EP + buffer which also used as running buffer in SPR system. After this step, 
regeneration of the surface was performed to remove the bound analyte from the ligand 
on the surface. This step is very important because it affects the binding activity of the 
surface for further experiments and life time of the chip. For regeneration step, NaOH 
was used and chip was prepared for further experiments.  
 
Figure 3.7 Representation of surface plasmon resonance. 
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3.2.6.   Fluorescent two- hybrid (F2H) assay 
 
3.2.6.1.   pcDNA 3.1/ myc- His (-) B- Nanobody BFP Vector Construction 
pcDNA 3.1/ myc- His (-) B vector which is a mammalian expression vector was selected 
since it had XhoI and BamHI cut sites in multiple cloning site in the correct order. 
Nanobody sequences such as Fersht original, Fersht CDR3 optimized and GFP CDR3 
optimized were obtained from pET22b plasmids via PCR with Fersht Original and Fersht 
CDR3 XhoI forward and reverse primers (Table 3.5). BFP protein sequence, on the other 
hand, obtained from PRLL BFP plasmid via PCR with linker forward and BFP reverse 
primer. 5’ end of nanobody reverse primers and 5’ end of linker primer is complementary 
to each other. PCR products were run on gel and gel extraction were carried out for each 
of them. Nanobody sequences with part of linker sequence and BFP sequence with part 
of linker sequence denatured at 95°C and annealed when temperature was gradually 
decreased. Before this reaction, control gel was run to see the concentrations of each DNA 
band. According to concentrations, 1:1 ratio was used for annealing the two DNA 
fragments. Gel extraction was carried out afterwards. In order to ligate nanobody 
sequences linked to BFP sequence to pcDNA 3.1/ myc- His (-) B vector, both insert and 
vector were cut via BamHI and XhoI enzymes (Table 3.6). After digestion, gel extraction 
was carried out and control gel were prepared to ligate both vector and inserts in 1:3 
ratios. Ligation product was transformed to DH5α. Single bacterial colonies were picked 
and their pDNAs were isolated. In order to confirm whether ligations worked or not, 
diagnostic digestion with known cut sites were carried out. 
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Table 3.6 Reaction conditions for PCR by Q5 polymerase 
5X Q5 reaction buffer 5 µl  
10 mM dNTP  0.5 µl 
10 µM forward primer  1.25 µl 
10 µM reverse primer  1.25 µl 
Template DNA (1 ng) 1 µl 
Q5 Polymerase 0.25 µl 
ddH2O  To 25 µl 
 
Table 3.7 Double digest with XhoI and BamHI of both vector and inserts 
 Insert pcDNA 3.1/ myc- His (-) B 
DNA 2 µg 2 µg 
CutSmart Buffer (NEB) 5 µl 3 µl 
XhoI 1 µl 1 µl 
BamHI 1 µl 1 µl 
ddH2O To 50 µl To 30 µl 
 
 
3.2.6.2.   PEI transfection of F2H- assay plasmids  
After 200.000 cell / well BHK cells were seeded in 6 well plate, 1 !g from each plasmid, 
TagGFP-p53, TagRFP- MDM4, pcDNA3.1/ myc- His (-) B- GBP-LacI and pcDNA3.1/ 
myc- His (-) B- Nanobody BFP were transfected with 12 !l PEI. 
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4.   RESULTS 
 
 
 
4.1.   Optimization of Nanobody Binding 
 
 
In this study we aimed to identify high affinity nanobodies binding to the human MDM4 
protein and test their ability to block the interaction between MDM4 and p53. We tested 
five nanobodies for this function (Table 4.1). Two of these nanobodies were used as a 
reference and optimized by in silico design. Reference nanobodies are from Yu et al., 
2009 which was previously developed against the p53 binding domain of MDM4 and 
from Kubala et al., 2010, which is against the green fluorescent protein (GFP). These will 
be referred as MDM4 Nb and GFP Nb respectively. These reference nanobodies were 
used to generate new nanobody candidates, which were optimized for binding to the p53 
binding domain of the MDM4 protein better than the references, by in silico mutagenesis 
of their complementarity determining regions (CDRs). The best candidate nanobodies 
were selected by molecular docking and steered molecular dynamics (Manuscript in 
preparation, Hacısüleymanoglu et al.). The Derived nanobodies are, MDM4 CDR3 Nb, 
MDM4 CDR1 CDR3 Nb and GFP CDR3 Nb. 
 
Table 4.1 Predicted molecular weights of nanobodies used in the study 
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4.1.1.   Periplasmic Expression 
 
To test the success of in silico affinity optimization on nanobody affinity, we expressed 
and purified the nanobodies shown in Table 4.1 in E.coli. Both the reference and the 
derived nanobodies have disulfide bonds. The cytoplasm of the bacterial systems is not 
suitable for disulfide bond formation because it is a reducing environment and for the 
formation and stability of disulfide bonds, an oxidizing environment is necessary 
(Stewart, Åslund, and Beckwith 1998). On the other hand, the bacterial periplasm has an 
oxidizing environment and expresses enzymes for disulfide bond formation. We aimed 
to direct our nanobodies to the periplasmic space for proper folding. For this purpose, we 
cloned these nanobody encoding cDNA’s into different bacterial expression plasmids, 
used these to transform bacteria and attempted to extract these nanobody proteins by 
different lysis and purification methods.  
 
First, we used the pET22 b (+) plasmid for the periplasmic production of nanobodies. The 
plasmid encodes an N terminal pelB leader sequence for directing nanobodies to the 
bacterial periplasm and a C- terminal His tag for affinity purification. Starting from the 
protein sequences of the five different nanobodies, we reverse translated protein 
sequences using the EMBOSS Backtranseq online tool (Rice, Longden, and Bleasby 
2000)(https://www.ebi.ac.uk/Tools/st/emboss_backtranseq/). Then sequences were 
commercially synthesized in the pET22 b (+) plasmid (https://www.biocat.com). We 
transformed the synthetic plasmids into the chemically competent Rosetta 2 DE3 pLYSs 
bacterial strain. This is a strain designed to express eukaryotic proteins at the high levels 
because it contains the pLYSs plasmid which expresses tRNAs for rare codons. This stain 
is designed to have low levels of basal expression before induction because the T7 
promoter which initiates insert transcription is blocked by the LacI protein which can be 
released by induction with IPTG, a lactose analog, that results in high levels of 
expression.  
 
We first attempted to express and purify nanobody proteins using a previously published 
protocol (McMahon et al. 2018).  For our initial attempt to express the MDM4 Nb (Yu et 
al. 2009), we prepared 3ml and 50 ml pre cultures, transferred these to an 1L culture and 
amplified the transformed bacteria overnight at 37 oC with vigorous shaking. We induced 
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protein expression with IPTG and harvested induced cells by centrifugation. We 
resuspended these cells in ice cold lysis solution containing sucrose and added ice cold 
water to induce osmotic shock. We separated soluble proteins from non-soluble cell 
debris and analyzed lysate, pellet and supernatant fractions by SDS gel electrophoresis. 
To capture any protein in the supernatant fraction, we loaded the supernatant onto a 
previously equilibrated His tag affinity column. The bound proteins were washed with a 
high salt buffer with low concentrations of imidazole in order to remove non-specific 
binding. Bound proteins were eluted using 400 mM and 600 mM imidazole. The protein 
contents of these different fractions were analyzed on an SDS-PAGE gel. (Fig. 4.1). 
 
 
 
Figure 4.1 Periplasmic nanobody expression using an osmotic shock protocol. Before 
His tag affinity column, the expressed MDM4 Nb protein was analyzed on a 14% SDS-
PAGE gel. The expected protein size is around 15 kDA. Compared to uninduced controls, 
IPTG induced samples contained a band at the expected size but this protein was 
predominantly localized in the pellet fraction and only a minor fraction was in the soluble 
supernatant.  
  
 
The appearance of a specific band at the expected size indicated that the constructed 
expression plasmid and the induction of expression was successful. But in the supernatant 
fraction, the amount of MDM4 Nb was not detectable. This may be due to the low 
concentration of protein because of the dilution of the nanobody protein during the 
osmotic shock procedure. To purify and concentrate this protein, we performed affinity 
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purification by binding the His tagged protein with a nickel affinity matrix and we 
performed elutions with increasing concentrations of imidazole, 400 mM and 600 mM 
(Figure 4.2).  
 
 
Figure 4.2 Periplasmic nanobody purification. MDM4 Nb expressed in 14% SDS-
PAGE gel was used and expected protein size is around 15 kDA.  
 
 
We could not purify MDM4 Nb with this protocol. Although there is no problem in 
induction, the nanobody proteins was insoluble and remained in the pellet fraction. This 
could be due to incorrect folding of these proteins in the periplasmic space or possibly 
due to problems in secretion into the periplasm even though they contained a pelB leader 
sequence. To increase the amount of soluble nanobodies, we tried to optimize the culture 
size and altered the composition of buffers used in the lysis. Lysis of bacterial cells in 
TSE buffer containing Tris, Sucrose and EDTA followed by ice- cold water for osmotic 
shock was successful (Quan et al. 2013). After lysis and centrifugation, we were able to 
detect nanobodies in the supernatant fractions. Unfortunately, the MDM4 Nb expressing 
Rosetta 2 DE3 pLYSs cells lysed during osmotic shock treatment, possibly due to the 
overexpression of this protein. However, GFP Nb expressing Rosetta 2 DE3 pLYSs cells 
were intact and could be lysed and proteins from these lysates were identified in the 
soluble fractions (Fig. 4.3). We tried expressing and extraction all five nanobodies using 
this protocol, but, similar to MDM4 Nb expressing bacteria, GFP CDR3 Nb expressing 
bacteria could not yield soluble protein in the supernatant after centrifugation (Figure 
4.3). 
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Figure 4.3 Periplasmic nanobody expression. GFP Nb and GFP CDR3 Nb was induced 
and their expression identified using 14% SDS-PAGE gels and we observed a band in the 
soluble fraction of the GFP Nb and not the GFP CDR3 Nb expressing lysates at the 
expected protein size, around 13.9 kDA.  
 
 
GFP Nb was induced clearly when compared to uninduced controls and also it was in the 
supernatant. On the other hand, we could not detect a clear induction of GFP CDR3 Nb 
likely due to the low resolution of this gel. We continued to purify the GFP Nb using a 
batch method for His- tagged proteins. After this observation, the next step which is, 
purification was applied for GFP Nb (Figure 4.4). We examined the fractions for the 
presence of His- tagged proteins by SDS-PAGE. The non- retained fraction was the 
fraction which contains proteins not binding to the cobalt resin. The fractions from the 
washing step were also collected and as before with affinity chromatography, we 
performed the elutions with increasing concentrations of imidazole (Figure 4.4). 
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Figure 4.4 Periplasmic nanobody purification. Non-retained, washing supernatants 
and the elutions of GFP Nb were examined by SDS-PAGE. GFP Nb was purified with 
His tag batch method. Concentrations of purified proteins in the eluted fractions were, 50 
mM Imidazole elution:  0.42 mg/ml, 100mM Imidazole elution: 0.26 mg/ml, 300Mm 
Imidazole elution: 0.02 mg/ml.  For long term storage, the 50 mM and 100mM Imidazole 
elutions were pooled with the addition of 20% glycerol and snap frozen in liquid nitrogen. 
14% SDS-PAGE gel was used and the expected protein size is around 13.9 kDA. 
 
 
For GFP CDR3 Nb, we performed colony screening (Figure 4.5). After transformation of 
the GFP CDR3 Nb encoding plasmid into the Rosetta2 pLysS bacterial expression strain, 
we observed that colonies formed were not uniform in size and shape and this finding 
raised the possibility that basal level of leaky expression of this protein may be toxic to 
bacterial cells and we questioned whether all colonies were capable of producing the 
nanobody or not. By using the protocol of Quan et al. 2013, we induced protein 
expression in small scale and tested the protein expression in several colonies selected 
from the transformation plate. After application of the osmotic shock lysis and the 
centrifugation, we observed that for most samples the pellet and supernatant were not 
clearly separated.                                                                         
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Figure 4.5 Colony screening for GFP CDR3 Nb expression. 7 colonies were screened. 
There were no positive colonies for GFP CDR3 Nb expression. 14% SDS-PAGE gel was 
used and expected protein size is around 13.9 kDA. 
 
 
Next, we performed colony screening to transformed bacteria expressing MDM4 CDR3 
Nb and MDM4 CDR1 CDR3 Nb.  We selected 3 colonies from each transformation plate 
and applied the same protocol that was performed on the GFP CDR3 Nb. Different from 
the previous protocol, after we applied osmotic shock and centrifugation, we applied 
sonication after the lysis buffer application because the pellet was sticky and difficult to 
load to the SDS-PAGE gel due to cell lysis. We used a whole cell lysis protocol which 
contains HEPES, NaCl, imidazole, TCEP, protease inhibitors and benzonase. The high 
viscosity of the pellet was decreased by DNA shearing and digestion by sonication and 
benzonase treatment. For sonication, we used Diagenode Bioruptor with a cycle 
consisting of 20 seconds on and 20 seconds off for 5 min. As before, the supernatant and 
pellet fractions were separated and analyzed by SDS-PAGE (Figure 4.6).  
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Figure 4.6 Colony screening for MDM4 CDR3 Nb and MDM4 CDR1 CDR3 Nb  
expression. There was no positive colonies for MDM4 CDR1 CDR3 Nb but for MDM4 
CDR3 Nb, there was induction but it was not clear due to the low resolution of the gel. 
14% SDS-PAGE gel was used and expected protein size is around 15 kDA. 
 
 
Because we were not able to obtain soluble nanobody proteins in the periplasmic 
expression systems, we decided to apply the whole cell lysis protocol instead of the 
osmotic shock protocol. We induced a 1L culture with 0.5mM IPTG, resuspended the 
pellet in lysis buffer and sonicated in a Qsonica Q500 sonicator with 5 seconds on and 10 
seconds off with amplitude 40%. We centrifuged the cell lysate again and loaded the 
supernatant to a column with 3 ml cobalt affinity resin. After several washes with IMAC 
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A buffer, we eluted bound proteins with 50mM, 100mM, 300mM and 600mM Imidazole 
containing elution buffer (Figure 4.7).  
 
 
 
Figure 4.7 Periplasmic nanobody purification with the whole cell lysis protocol. 
MDM4 CDR3 Nb was purified. Concentrations of nanobody proteins obtained in the 
various elution fractions were, 50 mM Imidazole elution:  0.8 mg/ml, 100mM Imidazole 
elution: 0.3 mg/ml.  For long term storage, the 50 mM and 100 Mm Imidazole elutions 
were pooled with the addition of 20 % glycerol and snap frozen in liquid nitrogen. 14% 
SDS-PAGE gel was used and expected protein size is around 15 kDA. 
 
 
To optimize the expression of the MDM4 Nb and GFP CDR3 Nb we performed colony 
screening and found positive colonies for bacteria transformed with MDM4 Nb 
expressing plasmids. For colony screening, we induced 25 ml cultures and boiled the 
pellets with 4x Laemmli Buffer at 95 oC and analyzed by SDS-PAGE. On the other hand, 
unfortunately we could not find any colonies expressing the GFP CDR3 Nb. This may be 
because of a problem with the expression vector which is being re-analyzed.  
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Figure 4.8 Colony screening for MDM4 Nb and GFP CDR3 Nb  expression. There 
were positive colonies for MDM4 Nb but there was no positive colony for GFP CDR3 
Nb. 14% SDS-PAGE gel was used and expected protein size was around 15 kDA for 
MDM4 Nb and 13 kDA for GFP CDR3 Nb.  
 
We choose the 6th colony from MDM4 Nb colony screening to continue with the protein 
purification and we applied the protocol for whole cell lysis His tag protein purification 
(Figure 4.9). For the GFP CDR3 Nb, colony screening was performed again but colonies 
were not positive. We induced a 1 L culture with 0.5mM IPTG and after cell lysis, 
supernatant fractions were separated by affinity chromatography using cobalt affinity 
columns.  
 
 
Figure 4.9 Periplasmic nanobody purification with the whole cell lysis protocol. 
MDM4 Nb was also purified with this method. Concentrations of nanobody proteins 
obtained in the various elution fractions were, 50 mM Imidazole elution:  0.34 mg/ml, 
100mM Imidazole elution: 0.15 mg/ml.  For long term storage, the 50 mM and 100 Mm 
Imidazole elutions were pooled with the addition of 20 % glycerol and snap frozen in 
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liquid nitrogen. 14% SDS-PAGE gel was used and expected protein size is around 15 
kDA. 
 
 
We re-attempted the identification of MDM4 CDR1 CDR3 Nb expressing bacteria by 
repeated colony screening. For new colony screenings, new transformations were carried 
out (Figure 4.10). We induced 25 ml cultures with 0.5mM IPTG and whole cell lysis was 
carried out with 4x Laemmli buffer at 95 oC.  From colony 3, we prepared a preculture 
for His tag affinity purification (Figure 4.11). We applied the same protocol for whole 
cell lysis to a 1 L culture. However, although there was the induction of nanobody, nearly 
all of the nanobody protein was stuck in the pellet. This failure may be due to the 
hydrophobicity of the protein itself or inappropriate induction conditions such as high 
IPTG concentrations that result in rapid induction which precludes the expression in the 
periplasm. 
 
 
 
Figure 4.10 Colony screening for MDM4 CDR1 CDR3 Nb expression. There are 
positive colonies for MDM4  CDR1 CDR3 Nb. 14% SDS-PAGE gel was used and 
expected protein size is around 15 kDA for MDM4 CDR1 CDR3 Nb.  
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Figure 4.11 Periplasmic nanobody purification with the whole cell lysis protocol. 
MDM4 CDR1 CDR3 Nb could not be purified because it was insoluble in the pellet 
fractions. 
 
 
Unfortunately, after repeated attempts, the MDM4 CDR1 CDR3 Nb protein was stuck in 
the pellet fractions. In order to optimize the induction time, we performed a time course 
induction of expression experiment from 5, 10 and 15 hours. We prepared 3 ml pre 
cultures and we performed induction inside 40 ml with 0.5 mM IPTG. Then we incubated 
cultures at 18 oC 180 rpm according to the time periods mentioned. After induction, we 
applied the whole cell lysis protocol with sonication. Unfortunately, 5 hours induction 
was not sufficient to express nanobody proteins in these bacteria, and while 10 and 15 
hours inductions revealed the presence of expressed proteins, these were again insoluble 
in the pellet fractions. We suspect this insolubility problem is due to the insoluble 
character of the specific protein (Figure 4.12).  
 
 
Figure 4.12 Time dependent periplasmic nanobody expression with whole cell lysis 
protocol. MDM4 CD1 CDR3 nanobody was expressed for 5 hours, 10 hours and 15 hours 
but failed to be expressed in the soluble fraction. 
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4.1.2.   Cytoplasmic Expression 
 
For cytoplasmic expression, we used the BL21 DE3 strain. However, the bacterial 
cytoplasm has a reducing environment which is not suitable for the formation of disulfide 
bonds. We transformed the SOX plasmid into these bacteria which expresses recombinant 
sulfhydryl oxidase enzyme into BL21 DE3 competent strain and after selection with 
chloramphenicol, we prepared a preculture and we made BL21 DE3 strain containing 
SOX plasmid competent again for transformation with nanobody expression plasmids. 
The sulfhydryl oxidase enzyme can form disulfide bonds in reducing environments 
(Nguyen et al. 2011). Nanobody plasmids used in cytoplasmic expression were different 
from those used for periplasmic expression. We cloned nanobody sequences from the 
pET22b plasmid into the pET28a plasmid which has no periplasmic leader peptide and 
has a C- terminal His tag for purification purposes.  The induction was also different from 
periplasmic induction, initially, because sulfhydryl oxidase enzyme was under control of 
an arabinose promoter, arabinose was added to the culture for 30 minutes at 30 oC. After 
this step, 0.5mM IPTG was added to induce nanobody protein for 4 hours at 30 oC. For 
colony screening to identify cytoplasmic expression, we chose to express the MDM4 Nb 
which was previously purified with periplasmic expression and two nanobodies which 
we could not purify with periplasmic production; MDM4 CDR1 CDR3 Nb and GFP 
CDR3 Nb. Colony screening results were positive for all three nanobodies (Figure 4.13). 
Surprisingly, GFP CDR3 which we could not express in periplasmic production, was 
expressed in this cytoplasmic expression system. Following this, we attempted 
solubilization and His tag affinity column chromatography for MDM4 CDR1 CDR3 in a 
1 L culture. After whole cell lysis unfortunately the nanobody was insoluble in the pellet 
fraction (Figure 4.14).   
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Figure 4.13 Colony screening for cytoplasmic expression. MDM4 Nb, MDM4 CDR1 
CDR3 Nb and GFP CDR3 Nb were expressed in BL21 DE3 bacteria containing the SOX 
plasmid. 14% SDS-PAGE gel was used and expected protein size is around 15 kDA for 
MDM4 Nb and MDM4 CDR1 CDR3 Nb, and 13.9 kDA for GFP CDR3 Nb.   
 
 
  
Figure 4.14 Cytoplasmic nanobody purification with the whole cell lysis protocol. 
MDM4 CDR1 CDR3 Nb was expressed in BL21 DE3 bacteria containing the SOX 
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plasmid. Nanobody stuck at pellet. 14% SDS-PAGE gel was used and expected protein 
size is around 15 kDA.  
 
 
After the observation of the MDM4 CDR1 CDR3 Nb in the insoluble fractions, we 
attempted the use the Bugbuster® protein extraction reagent. This is a reagent that 
disrupts the E.coli cell wall. It contains Tris-buffer based mixture of several non-ionic 
and zwitterionic detergents which enables degradation of the cell wall without causing 
denaturation of proteins. After arabinose and IPTG induction, as mentioned before, we 
harvested the cells via centrifugation and weighed the dry pellet. We resuspended the 
pellet with Bugbuster reagent using 5 ml Bugbuster reagent per gram of wet cell paste. 
Benzonase and protease inhibitors were also added in this step. We mixed the cell 
suspension for 20 minutes and centrifuged again to separate the soluble supernatant and 
pellet fractions which were analyzed by SDS-PAGE. Unfortunately, the Bugbuster 
reagent did not work for the MDM4 CD1 CDR3 Nb which was again stuck in the 
insoluble pellet (Figure 4.15). 
 
 
 
 
Figure 4.15 Cytoplasmic nanobody purification with the Bugbuster® protocol. 
MDM4 CDR1 CDR3 Nb was expressed in BL21 DE3 bacteria containing SOX plasmid 
and Bugbuster reagent was used for lysis of the cell. Nanobody stuck at pellet. 14% SDS-
PAGE gel was used and expected protein size is around 15 kDA.  
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We also attempted to express the MDM4 Nb as a soluble protein using the whole cell 
lysis protocol but could not obtain soluble protein for this protein as well (Figure 4.16). 
This may be due to the temperature which is 30oC for induction or IPTG concentration. 
To understand the reason, we carried out temperature, IPTG and time dependent protein 
expression with 25 ml cultures. We induced all cultures with arabinose initially to express 
the sulfhydryl oxidase enzyme and induced with IPTG. There were two groups for 
temperature which were 30oC for 4 hours of induction and 18oC overnight induction. 
Each group was induced with different IPTG concentrations 0.1mM, 0.3mM and 0.5mM. 
We also tested the expression time- dependence of solubility induced at 30oC with 0.5mM 
IPTG for 1 hour, 2 hours, 3 hours and 4 hours (Table 4.2). For all groups, we harvested 
the cells and lysed with the whole cell lysis buffer and sonicated using the Bioruptor 
Sonicator and analyzed by SDS-PAGE (Figure 4.17).  
 
 
 
Figure 4.16 Cytoplasmic nanobody purification with the whole cell lysis protocol. 
Positive colony from MDM4 Nb colony screening was chosen and large culture of 
MDM4 Nb was prepared and expressed in BL21 DE3 bacteria containing SOX plasmid 
and whole cell lysis buffer used for lysis of the cell. Nanobody stuck at pellet. 14% SDS-
PAGE gel was used and expected protein size is around 15 kDA.  
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Table 4.2 Groups for temperature, time and IPTG dependent expression 
 
 
 
  
 
Figure 4.17 IPTG, temperature and time dependent cytoplasmic nanobody 
expression with the whole cell lysis protocol. There was no difference between groups 
and in all of them MDM4 Nb proteins were stuck in the insoluble pellet fractions.  
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In these dose- response and time course experiments, we observed that in general 
cytoplasmic expression of nanobodies in the BL21DE3 SOX strain did not change much 
with the changing parameters. The SOX plasmid used in this study was a gift from Prof. 
Ario DeMarco. Unfortunately, because we did not have and appropriate plasmid map for 
this vector. We could not be certain that the protein expression and induction were 
sufficiently upregulated before nanobody expression. Colony screening was not 
successful in identifying soluble proteins in the cytoplasm (Figure 4.18). 
 
In summary, we purified GFP Nb, MDM4 Nb and MDM4 CDR3 Nb. MDM4 CDR1 
CDR3 and GFP CDR3 Nb could not be purified. GFP Nb was expressed in the periplasm 
and purified with the osmotic shock application. Also, we expressed MDM4 Nb and 
MDM4 CDR3 Nb in the periplasm and purified these with the whole cell lysis (Table 
4.3). 
 
 
 
Figure 4.18 Colony screening for cytoplasmic expression.  MDM4 CDR3 Nb and 
GFP Nb were not detected in the soluble fraction. 
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Table 4.3 Methods used for the expression and purification of nanobodies 
 
 
 
 
 
4.2.   Surface plasmon resonance (SPR) for comparing binding affinities of 
nanobodies 
 
 
We used surface plasmon resonance to find binding affinities of the purified nanobodies. 
We used the Biacore T200 SPR machine for this purpose. The first step was pH scouting 
to decide the pH of the acetate buffer which is used for the immobilization of the p53 
binding domain of the MDM4 protein. In our first trial, we used 10 !g/ ml MDM 4 protein 
and contact time was 180 seconds and the flow rate was 5 !l/ min. Arbitrary response 
units (RU) reflecting the change in refractive index and the binding to the surface were 
plotted as a function of time. However, we observed a very sharp increase when ligand 
was injected so we decided to decrease the concentration of the MDM4 protein and the 
flow rate, and decrease the contact time of the protein with the chip surface. In our second 
trial, we used 2,5 !g/ ml MDM4 protein and contact time was 120 seconds and the flow 
rate was 10 !l/ min (Figure 4.19). We chose the pH of the acetate buffer as 4.5 and 
performed immobilization of the MDM4 protein. The chosen pH of 4.5 was higher 
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compared to the pH of the surface which is 3.5 and lower than the isoelectric point of the 
p53 binding domain of MDM4 protein. We used the same values and buffer for 
immobilization. NHS/ EDC was used to activate the surface and further ligand with 2,5 !g/ ml concentration was injected over the surface. After this step, NaOH was used to 
block the surface of the chip to deactivate unreacted esters. At the end of the 
immobilization, 500 RU of material was deposited onto chip surface (Figure 4.20).  
 
 
 
Figure 4.19 pH scouting experiment 10	!g/ ml and 2,5 !g/ ml MDM4 was used. When 
10	!g/ ml was used RU increased immediately after injection so concentration was 
decreased to 2,5 !g/ ml. pH 4.5 was chosen for acetate buffer.  
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Figure 4.20 Immobilization of MDM4 on CM5 chip 2,5 !g/ ml of p53 binding domain 
of MDM4 was immobilized with contact time 120 seconds and rate 10 !l/ min. 500 Net 
RU was observed. 
 
 
After immobilization of the MDM4 on the CM5 chip we performed nanobody binding 
kinetics experiments. As an analyte, we used three different nanobodies, MDM4 Nb, 
MDM4 CDR3 Nb and GFP Nb. MDM4 Nb was our positive control because it is our 
reference nanobody and GFP Nb was a negative control because it is specific to GFP and 
not to MDM4. We could not test the remaining proteins, MDM4 CDR1 CDR3 Nb and 
GFP CDR3 Nb, with SPR because we could not obtain purified protein. Three nanobodies 
were injected separately on the CM5 chip containing MDM4 protein and we used five 
different concentrations, 1000 nM, 2000 nM, 3000 nM, 4000 nM and 5000 nM. For all 
dilutions, we used HBS- EP + buffer which was also running buffer.  
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We compared the resonance units (RU) for all of the nanobodies at the same 
concentration. In all concentrations, the MDM4 CDR3 Nb exhibited higher response units 
compared to our reference nanobody which was the MDM4 Nb protein. Thus, MDM4 
CDR3 Nb binds better compared to the reference nanobody. However, there were 
fluctuations when the concentrations were increased.  For example, at 1000 nM, MDM4 
CDR3 and MDM4 Nb exhibited 29,2 RU and 17,3 RU respectively. But when we 
increased the concentration to 2000 nM, the responses were 20,7 and 6.3 RU for MDM4 
CDR3 Nb and MDM4 Nb respectively. This unproportional increase in apparent binding 
precludes the performance of binding kinetics analysis (Figure 4.20). However, these 
preliminary experiments indicate that the in silico optimized anti- MDM4 nanobodies can 
in fact have a better binding affinity to MDM4 than the reference nanobody. 
 
 
 
 
Figure 4.21 Binding at different concentrations of the MDM4 Nb, MDM4 CDR3 Nb 
and GFP Nb. 
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4.3. Fluorescent two-hybrid (F2H) assay for the interaction between nanobodies 
and MDM4 protein 
 
 
To attempt to measure the effects of nanobody binding on the MDM4-p53 interaction in 
the cellular context, we performed the F2H assay in tissue culture cells analyzed under 
fluorescent microscopy. The F2H is a live cell, protein-protein interaction investigating 
assay which uses fluorescent live-cell microscopy to detect the protein interactions as a 
compound or an inhibitor is given to the system. We used baby hamster kidney cells 
(BHK) for this assay and transfected several plasmids containing our proteins of interest 
linked to fluorescent proteins which are enabling visualization of the interaction (Figure 
4.21). The first plasmid we expressed, p53 linked to the TagGFP protein and the second 
one expressed the p53 binding domain of MDM4 protein fused to the TagRFP protein. 
The third plasmid expressed a LacI- GFP binding protein (GBP) fusion which anchored 
these fluorescent proteins to lac operator sequences that were genetically inserted into an 
unknown locus in the genome of these BHK cells. We expressed three different nanobody 
sequences which were MDM4 Nb, MDM4 CDR3 Nb and GFP CDR3 Nb. All of these 
nanobodies were turned into chromobodies because they were expressed as fusion 
proteins with Tag BFP protein. We used BHK cells which were genetically modified by 
stable transfection to contain lac operator sites in their genome. 
 
We seeded BHK cells onto tissue culture plates and co-transfected these four plasmids. 
The LacI- GBP plasmid expressed the fusion protein which was binding to LacI operators 
and Tag GFP protein which is part of the TagGFP- p53 fusion interacted with the GBP 
component of LacI-GBP. This led to the formation of green focus in the nucleus. In fact, 
the GBP protein is a GFP binding protein that is an anti- GFP nanobody. The p53 protein 
interacted with the p53 binding domain of MDM4 protein which was fused to TagRFP 
expressed as a fusion protein. As a result, we observed a green focus co-localized red 
focus. If the expressed nanobodies were interacting with the p53 binding domain of 
MDM4, the red focus disappeared from the nucleus and it was released into the cytoplasm 
which was observed as a diffuse red fluorescence in the cytoplasm and in the nucleus 
(Figure 4.22).  
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Figure 4. 22 Plasmids used in fluorescent two hybrid assay. 
 
 
 
Figure 4. 23 Mechanism of the fluorescent two hybrid assay. LacI GBP fusion protein 
localized to lacI promoters integrated into the BHK cell genome and expressed TagGFP 
p53 protein binds to GBP and it is localized into a focus in the nucleus. When there is no 
nanobody expression, MDM4 TagRFP protein binds to p53 protein and it co-localized 
with p53 protein in the nucleus. However, when there is nanobody expression, if 
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nanobody is capable of binding to MDM4, MDM4 protein can be separated from p53 and 
migrate to cytoplasm and there will be no co- localization. 
 
Before the experiments with nanobodies, to verify the system, we transfected different 
combinations of F2H plasmids into BHK cells. When we transfected the MDM4 Tag RFP 
plasmid and the Tag GFP p53 plasmid, there was no foci formation due to the lack of 
LacI- GBP fusion plasmid which was normally docked on the lacI operators in the 
genome. The second group was, LacI- GBP fusion plasmid and MDM4 Tag RFP, we 
observed TagRFP in the cells but there were no foci in the nucleus. The third group was, 
LacI- GBP fusion plasmid and TagGFP p53 plasmid and we observed green dots in the 
nucleus showing that for localization of p53 into the genome, LacI- GBP fusion plasmid 
was needed. In the last group, we transfected all plasmids together and observed both 
green and red dots co- localized in the nucleus (Figure 4.23).  
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Figure 4.24 Verification of protein- protein interaction and the disruption of 
interaction by nanobodies using the F2H assay. Different combinations of three 
plasmids from F2H assay were transfected to BHK cells. Red and green dots co- 
localized when three plasmids transfected together. 
 
 
In the second part, we transfected our three nanobody plasmids containing MDM4 Nb, 
MDM4 CDR3 and GFP CDR3 Nb along with these F2H assay plasmids. For this 
experiment, we used 1 !g from each plasmid and transfected them into BHK cells using 
PEI reagents. After several trials, we could not observe the nanobodies fused with BFP 
after 24 hours, their expression was slow compared to GFP and RFP. We also checked 
the cells after 36 hours but GFP and RFP expression decreased after 36 hours and dots 
inside the nucleus could not be seen so we decided to check the cells 28 hours after the 
transfection. We used a fluorescent inverted Zeiss Live Cell Microscope. Tile regions 
were set at 20x and 25 tile regions were selected from the middle of each well.  
 
As negative control that only expressed BFP but no nanobody fusion, we used the pRRL 
plasmid. BFP fusion plasmids were transfected to BHK cells together with F2H assay 
plasmids. Initially, we focused on green dots which were foci localized TagGFP- p53 
proteins. After finding these spots manually, we counted co- localization with red dots 
which were localized MDM4- TagRFP proteins, in the GFP and RFP channels. For each 
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group, pRRL plasmid, MDM4 Nb, MDM4 CDR4 Nb and GFP CDR3, we counted cells 
with only green dots and co-localized green and red dots and found the percentages 
(Figure 4.25). pRRL plasmid containing negative control had 83% co-localization of 
green and red dots which we expected. On the other hand, we observed 90% only green 
dots in MDM4 Nb containing BHK cells. This result verified that our reference nanobody, 
MDM4 Nb, worked very efficiently and separated the MDM4 and p53 complex. On the 
other hand, in MDM4 CDR3 Nb and GFP CDR3 Nb containing BHK cells we observed 
37% and %34 only GFP. This means in silico designed nanobodies also interacts with the 
p53 binding site of MDM4 but not as effectively as MDM4 Nb (Figure 4.24). 
 
Thus, although the in vitro results on SPR measured MDM4 CDR3 nanobody affinity 
displays the highest affinity, the in vivo results were quite dramatic.  Here the MDM4 Nb 
not only bound best but also displayed the highest affinity in disrupting the MDM4 and 
p53 interaction. 
 
 
 
Figure 4.25 A bar graph showing the amount of the GFP foci containing cells and 
the percentages of co-localization in these cells. 
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Figure 4.26 F2H assay with nanobodies. Nanobodies transfected together with F2H 
assay plasmids. In the pRRL plasmid group which was the negative control, we observed 
co-localization of green and red foci. In the MDM4 Nb plasmid transfected group which 
was the positive control, we observed only green foci but red dots mostly disappeared. In 
MDM4 CDR3 Nb and GFP CDR3 Nb transfected groups, there was green foci but only 
some of the red foci were disappeared.  
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5. DISCUSSION 
 
 
 
Regulation of p53 protein is very important to prevent cancer development. In 50 % of 
cancers, p53 gene is mutated, in most of the remainder, there is an overexpression of the 
negative regulators of the p53 protein which results in a malfunction of this pathway (Hu 
et al. 2006). For human cancers, where there is an overexpression of MDM2, antagonists 
for MDM2 such as Nutlin-3a that activate the p53 tumor suppressor were developed 
(Vassilev 2004). However, for some cancer types, the use of these antagonists is not 
effective because of active MDM4 protein which can also inhibit the activity of the p53 
protein. Moreover, in some cancers, there is an overexpression of MDM4, which makes 
it difficult to activate p53.  With these observations, there is a need for antagonists of 
MDM4. In this study, we aimed to discover antagonists for MDM4 as nanobodies because 
they are very good candidates for tumor therapeutics because of their small size and high 
penetration ability to tumor cells (Van Audenhove and Gettemans 2016). However, the 
production of nanobodies by either injection of the antigen to llamas or phage/ yeast 
display and selection methods is time consuming and is expensive. We aimed to generate 
an alternative method which is faster and less expensive. In this method, novel 
nanobodies were generated from reference nanobodies by changing their 
complementarity determining regions (CDRs). In previous work, in silico methods were 
used to select these nanobodies that were predicted to have high stability and high binding 
affinity towards the p53 binding site of MDM4. The best candidates were selected by 
energy minimization and molecular dynamics. In this thesis I attempted to optimize the 
expression and purification of several of these candidate nanobodies in bacterial systems. 
Also, I determined the binding affinity using both in vivo and in vitro methods. 
 
Firstly, we optimized the expression of nanobodies in bacteria. There were two reference 
nanobodies: MDM4 Nb from Yu et al. 2009 and GFP Nb from Kubala et al. 2010. We 
Other generated three ‘optimized’ nanobodies that were similar to these reference 
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nanobodies. Thus in total five different nanobodies were expressed. We first attempted to 
produce these nanobodies by periplasmic expression. Nanobody cDNA sequences were 
synthesized and inserted into the pET22b plasmid. This plasmid has an N- terminal pelB 
sequence for exporting nanobodies to the periplasmic space for disulfide formation and 
correct folding and a C- terminal His tag for affinity purification purposes. We chose the 
Rosetta 2 DE3 pLysS strain for expression because it has an extra plasmid which 
expressed rare codon tRNAs, that make it easier to express eukaryotic proteins. 
 
The general problem with periplasmic expression and osmotic shock for purification was 
unwanted cell lysis. During the application of the protocol, sticky cells were formed and 
it was difficult to further process bacterial pellets. This may be due to the toxicity of the 
nanobodies. We encountered cell lysis especially during the culture of high volumes (eg 
2 L). Bacteriophage contamination is also a possibility but was deemed unlikely because 
we observed this lysis in different bacterial strains and stocks. We also encountered cell 
lysis when we used Terrific Broth (TB), a more enriched medium compared to LB, that 
results in more division and larger population size. While we could express the MDM4 
Nb, MDM4 CDR3 Nb and GFP Nb proteins in the periplasmic space, we could only 
obtain the GFP Nb in the soluble fraction with the osmotic shock protocol. We purified 
the other two nanobodies using the whole cell lysis protocol. We were not successful in 
expressing the GFP CDR3 Nb, which can be seen from colony screening experiments. 
This can be due to a problem in the expression plasmid itself and in order to solve it 
cloning into another periplasmic vector can be tried. In addition to this, we successfully 
expressed the MDM4 CDR1 CDR3 Nb but could not successfully purify this protein from 
the soluble fractions regardless of the expression (periplasmic or cytoplasmic) and 
purification (osmotic shock or whole cell lysis) conditions. The changes in the CDR1 
region could affect the solubility of the protein possibly affecting the folding of the 
nanobody, sending the protein into bacterial inclusion bodies. Expression in the presence 
of different detergents may be a possibility to solubilize this protein.  
 
For cytoplasmic expression, we cloned nanobody sequences into the pET28a vector and 
used the BL21 DE3 strain containing the Sox plasmid. While all nanobodies (except 
MDM4 CDR1 CDR3 Nb) were expressed as evidenced by colony screening, we could 
not obtain these nanobodies in soluble fractions and all of the nanobodies were stuck at 
the pellet. To optimize this solubilization, we attempted time dependent and IPTG 
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concentration dependent experiments but could not see nanobodies in the in the soluble 
phase. The expression of enzymes from the Sox plasmid was not determined and in their 
absence disulfide bond requiring nanobody proteins may have formed aggregates in the 
cytoplasm. Also the BL21 DE3 strain, unlike the Rosetta 2 DE3 pLysS strain does not 
encode rare codons tRNAs and may not be suitable for the expression of some eukaryotic 
proteins. Because the Rosetta 2 DE3 pLysS strain contains a plasmid encoding these 
tRNAs providing chloramphenicol resistance, it cannot be transformed with the Sox 
plasmid which also contains chloramphenicol resistance. The expression of nanobody 
proteins may be more suitable in mammalian cell lines such as the commonly used CHO 
cell line.  
 
Secondly, we tested the affinity of purified nanobodies with surface plasmon resonance. 
We covalently immobilized a previously synthesized domain of MDM4 containing the 
p53 binding site on the CM5 chip and flowed soluble purified nanobodies over this chip. 
While we could detect binding of the nanobodies to the MDM4 protein, the use of a larger 
domain of MDM4 which folds correctly may provide a better system to detect the affinity 
of these nanobodies. The shape or size of the p53 binding site may not be suitable due to 
the defect in folding which may result in failed nanobody binding. Also, the chips with 
MDM4 protein were repeatedly used to test the binding of multiple nanobodies. The 
immobilized protein may be harmed by the regeneration cycles, decreasing the effective 
MDM4 protein on the surface. 
 
Finally, we used a fluorescent two hybrid assay to assess the binding of selected 
nanobodies in an in vivo setting. We excluded GFP Nb because F2H assay contains GFP 
protein and GFP Nb can bind to GFP protein causing defect in F2H assay mechanism. In 
addition to the GFP Nb, we excluded the MDM4 CDR1 CDR3 Nb from the F2H assay 
because we could not purify this protein in vitro and we predicted that in vivo expression 
may also be problematic. As a negative control in the F2H assay, we used the pRRL 
plasmid which expressed the BFP protein. The nanobodies that we expressed in these 
BHK cell line all had BFP tags at their C terminus. Unfortunately, BFP expression was 
not robust as the expression of the other fluorescent proteins such as GFP and RFP. 
problem in BFP expression We observed maximal GFP and RFP after 24 hours but we 
observed BFP protein only after 36 hours.  
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To analyze molecular interactions in vivo, we initially identified green foci in the nucleus 
containing the p53- GFP fusion protein and counted the cells containing overlapping red 
foci. We assessed the activity of nanobodies in disrupting the p53- MDM4 interaction by 
determining the number of lost co-localization. While our positive control which is the 
MDM4 Nb, 90% of the analyzed cells contained only green fluorescent foci, in our 
negative control in 83% of the green fluorescent foci containing cells there was also red 
fluorescent focus co-localization. In the cells that express MDM4 CDR3 Nb and GFP 
CDR3 Nb, co-localization was between our positive and negative controls indicating that 
the original MDM4 nanobody was more effective in disrupting the MDM4-p53 
interaction. Because the F2H assay can also be used to assess the interaction between 
MDM2 and p53, the specificity of the same nanobodies in disrupting this interaction may 
increase the impact of the disruption of the MDM4-p53 interaction. 
 
In summary, both the surface plasmon resonance and F2H assay needs some optimization 
experiments. However, we achieved to show the effect of nanobodies in vivo with the 
F2H assay for the first time and showed that in silico designed nanobodies had some 
activity too which can be developed more with in silico modelling experiments and trials 
with more nanobody candidates. The F2H assay can be used for screening of several 
different nanobodies. We aim to try high number of new in silico designed candidates 
with both SPR and F2H assay. Also novel nanobodies targeting the MDM4 p53 can be 
selected from a yeast display nanobody library, providing larger numbers of candidate 
nanobodies. It is of great interest to compare the affinity and activity of in silico designed 
nanobodies with those selected from yeast display libraries.  
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APPENDIX A- Chemicals 
 
 
 
 
Chemicals and Media Components Supplier Company 
2-Mercaptoethanol Sigma, Germany 
Acetic acid (glacial) Merck Millipore, USA 
Acrylamide/Bis-acrylamide (30%) Sigma, Germany 
Agarose Sigma, Germany 
Ammonium Persulfate Sigma, Germany 
Ampicilin Sodium Salt Sigma, Germany 
Boric Acid Molekula, France 
Chloramphenicol Deva, Turkey 
Coumaric Acid Sigma, Germany 
Coomassie Blue Brilliant Blue R Sigma, Germany 
Distilled Water Merck Millipore, USA 
DMEM Thermo Fischer Scientific, USA 
DMSO Sigma, Germany 
DNA Gel Loading Dye, 6X NEB, USA 
DTT Fermentas, USA 
EDTA Sigma, Germany 
Ethanol Sigma, Germany 
Ethidium Bromide Sigma, Germany 
Fetal Bovine Serum Thermo Fischer Scientific, USA 
Glutathione Sepharose 4 Fast Flow GE Healthcare Life Sciences, USA 
Glycerol Sigma, Germany 
Glycine Sigma, Germany 
HBSS Thermo Fischer Scientific, USA 
HEPES Sigma, Germany 
HisPure Cobalt Superflow Agarose Thermo Fischer Scientific, USA 
Hydrochloric Acid 
 
Sigma, Germany 
Hydrogen peroxide        Sigma, Germany 
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Imidazole Sigma, Germany 
IPTG Fermentas, USA 
Isopropanol Sigma, Germany 
Kanamycin Sulfate Thermo Fischer Scientific, USA 
LB Agar Sigma, Germany 
LB Broth Invitrogen, USA 
L-Glutathione reduced Sigma, Germany 
Luminol Sigma, Germany 
Methanol Sigma, Germany 
PBS Thermo Fischer Scientific, USA 
Penicillin/Streptomycin Thermo Fischer Scientific, USA 
PIPES Sigma, Germany 
Potassium Acetate Merck Millipore, USA 
Protease Tablets (EDTA-free) Roche, Germany 
RNase A Roche, Germany 
SDS Sigma, Germany 
Sodium Azide Amresco, USA 
Sodium Chloride Amresco, USA 
Sodium Hydroxide Sigma, Germany 
TEMED AppliChem, Germany 
TCEP Sigma, Germany 
Terrific Broth Sigma, Germany 
Tris Base Sigma, Germany 
Tris Hydrochloride Amresco, USA 
Trypan Blue Solution Thermo Fischer Scientific, USA 
Tween20 Sigma, Germany 
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APPENDIX B- Equipment 
 
 
 
Equipment Supplier Company 
Autoclave HiClave HV-110, Hirayama, Japan 
Balance Isolab, Germany 
Biomolecular Imager ImageQuant LAS 4000 mini, GE Healthcare 
Life Sciences, USA 
Centrifuge 5418R Eppendorf, Germany 
5702 Eppendorf, Germany 
5415R Eppendorf, Germany 
Allegra X-15R, Beckman Coulter, USA 
Sorvall Lynx 6000, Thermo Scientific, USA 
CO2 Incubator Binder, Germany 
Column HiLoad 16/60 Superdex p75, GE Healthcare 
Life Sciences, USA 
Countless II Automated Cell Counter Thermo Fischer Scientific, USA 
Deepfreeze -80°C, Forma 88000 Series, Thermo Fischer 
Scientific, USA 
-20°C, Bosch, Germany 
Electrophoresis Apparatus VWR, USA 
BIORAD, USA 
Filters (0.22µm and 0.45µm) Merk Millipore, USA 
Freezing Container Mr. Frosty, Thermo Fischer Scientific, USA 
Gel Documentation Gel Doc EZ, Biorad, USA 
Heater Thermomixer Comfort Eppendorf, Germany 
Hemocytometer Neubauer Improved, Isolab, Germany 
Ice Machine AF20, Scotsman Inc., USA 
Incubator Shaker Innova 44, New Brunswick Scientific USA 
Laminar Flow HeraSafe HS15, Heraeus, Germany 
HeraSafe HS12, Heraeus, Germany 
Liquid Nitrogen Tank Taylor-Wharton, 300RS, USA 
Magnetic Stirrer SB162, Stuart, UK 
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Microliter Pipettes Thermo Fischer Scientific, USA 
Microscope Primovert, Zeiss, Germany 
CK40, Olympus, Japan 
In Cell Analyzer 2500HS, GE Healthcare Life 
Sciences, USA 
Microwave Oven Bosch, Germany 
pH Meter SevenCompact, Mettler Toledo, USA 
Refrigerator Bosch, Germany 
Arcelik, Turkey 
Panasonic, Japan 
 Thermo Fischer Scientific, USA 
Reusable Filter Holder with Receiver Nalgene, USA 
RTCA system ACEA Biosciences, USA 
Sonicator Qsonica Q500, USA 
Spectrophotometer NanoDrop 2000, Thermo Fischer Scientific, 
USA 
Ultrospec 2100 pro, Amersham Biosciences, 
UK 
Surface Plasmon Resonance System BIACORE T200, GE Healthcare Life Sciences, 
USA 
Thermal Cycler C1000 Touch, Biorad, USA 
PTC-200, MJ Reseach Inc., Canada 
Vortex VWR, USA 
Water Bath Innova 3100, New Brunswick Scientific, USA 
 
 
APPENDIX C- Molecular Biology Kits 
 
 
 
GenElute Agarose Spin Columns Sigma-Aldrich, USA 
InsTAclone PCR Cloning Thermo Fischer Scientific, USA 
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NucleoSpin Gel and PCR Clean-up Macherey-Nagel, USA 
PureLink Genomic DNA Mini Kit Invitrogen, USA 
Purelink HiPure Plasmid Midiprep Kit Invitrogen, USA 
PureLink Quick Gel Extraction Kit Invitrogen, USA 
Zero Blunt TOPO PCR Cloning Kit for 
Sequencing 
Thermo Fischer Scientific, USA 
ZymoPure Plasmid Maxiprep Kit Zymo Research, USA 
 
APPENDIX D- DNA and Protein Molecular Weight Marker 
 
 
 
 
 
 
 
 
 
Figure D1. GeneRuler DNA 
Ladder Mix (SM0331), Thermo  
Fischer Scientific, USA 
Figure D2. Color Prestained 
Protein Standard, Broad 
Range (11-25 kDa) (P7712S), 
New England Biolabs 
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APPENDIX F- Plasmid Maps 
 
 
 
 
Figure F1. The plasmid map of pET22b 
 
 
Figure F2. The plasmid map of pET28a 
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Figure F3. The plasmid map of pcDNA3.1 Myc His B (-) 
 
 
 
Figure F4. The plasmid map of pRRL Tag BFP Plasmid  
 
 
